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                 Abstract  
 
Background: Group B streptococcus (GBS) is regarded as one of the most 
important causes of maternal and neonatal morbidity and mortality in many parts of 
the world. GBS recto-vaginal colonization is important in the health of a mother and 
her neonate, especially in developing countries. Maternal vaginal colonization with 
GBS at the time of delivery can cause vertical transmission to the neonate. 
Multilocus sequence typing (MLST) is a technique used to characterize microbial 
isolates by means of sequencing internal fragments of housekeeping genes and has 
the advantage of reproducibility and has been shown to correlate with the other 
typing techniques and thus has emerged as the standard for delineating the clonal 
population of GBS. The study aimed to investigate the epidemiology of GBS 
colonization among pregnant women and their neonates, and to characterize the 
isolates by multilocus sequence typing technique at Dr George Mukhari Academic 
Hospital, Pretoria. 
Methodology: A total of 413 pregnant women who visited the antenatal clinic were 
recruited and screened. Participants were interviewed using a questionnaire to 
gather demographic and other relevant information such as history of current 
pregnancy, previous miscarriages and still births. Samples from maternal rectum and 
vagina as well as neonate ear and umbilical cord were taken for culture using colistin 
and nalidixic acid (CNA) blood agar and incubated for 24-48 hours. If negative after 
48 hours, Todd-Hewitt broth was subcultured after 18-48 hours onto sheep blood 
agar. Multilocus sequence typing (MLST) was used to characterize seven group B 
streptococcus isolates collected at Dr George Mukhari academic hospital. Fragments 
of seven housekeeping genes were amplified by polymerase chain reaction (PCR) 
for each strain and sequenced. CLC bio software (Inqaba biotech, South Africa; 
Pretoria) was used to analyse sequenced loci and UPGMA dendrogram was 
constructed. 
Results: The colonization rate for GBS in pregnant women and their neonates was 
30.9% and 0%, respectively. A higher proportion of GBS were isolated from the 
rectum (37.9%) as compared to the vagina (20.6%). Most socio-economic, 
demographic and obstetric factors analysed were not significantly associated with 
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GBS colonization. On 128 positive samples, the results of Todd-Hewitt enrichment 
broth and direct plating method using CNA were compared. A total of 45.3% of 
colonised were positive on direct selective agar (CNA); an additional 54.7% samples 
were recovered from Todd-Hewitt broth. Three genes (adhP, glnA and tkt) were 
sequenced successfully for six samples (1, 2. 4,6,12 and 65). The UPGMA tree with 
1000 bootstrap showing the relationship between six samples was drawn.  
Conclusion: This study revealed that pregnant women of all ages are at risk of 
group B streptococcus colonization. Group B streptococcus was common among 
pregnant women at Dr George Mukhari Academic Hospital. No socio-economic risk 
factor was associated with group B streptococcus colonization. Results confirm that 
the combination of Todd-Hewitt broth and CNA agar plate is a time saving and 
sensitive method. The allelic profile, characteristics such as G+C (guanine+cytosine) 
content and dN/dS ratio were not analysed because of the smaller sample size used 
in this study, which shows that the MLST method was unsuccessful in this study. 
The UPGMA tree based on differences in consensus of the isolates showed that all 
group B streptococcus isolates are clustered and descend from a single node. 
Keywords: Epidemiology, Group B streptococcus, Multilocus sequence typing 
(MLST), colonization, pregnant women, neonates, Dr George Mukhari Academic 
Hospital. 
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CHAPTER 1 
1. INTRODUCTION 
Streptococcus agalactiae, known as group B streptococcus (GBS), is a Gram-
positive opportunistic pathogenic bacterium of the genus Streptococcus. It is a 
commensal organism in humans but can cause life threatening infection in 
susceptible hosts such as neonates, pregnant women and non-pregnant adults with 
chronic illnesses. Group B streptococcus exists as normal flora in genitourinary and 
gastrointestinal tracts in humans (Shen et al., 2001). The bacterium can be 
transferred from the vagina to the newborn babies during parturition, and this is 
frequent in developing countries (Javanmanesh and Eshraghi, 2013). 
Group B streptococcus causes invasive disease such as early-onset sepsis and 
pneumonia (Johri et al., 2006; Busetti et al., 2007) and late-onset infections such as 
meningitis in newborn babies making it one of the leading neonatal causes of 
morbidity and mortality (Yang et al., 2012). In pregnant women, it causes 
chorioamnionitis, urinary tract infection and wound infection in immunocompromised 
non-pregnant adults or those with underlying conditions (McKenna and Lams, 1998; 
Gonza´lez-Outeirin˜o et al; 2004). 
The major reservoirs for group B streptococcus are reported to be the vagina and the 
rectum, and the colonization of these regions is a risk factor for subsequent infection 
in pregnant women and newborns (Sharmila et al., 2011; Yang et al., 2012). Vertical 
transmission from the colonized mother to the newborn is the major risk factor for 
early-onset infection, including ascending intra-uterine and intrapartum infection, 
especially during vaginal deliveries (Busetti et al., 2007; Yang et al., 2012).  
 
Maternal factors predisposing to invasive neonatal infection include the following: 
high genital inoculums with group B streptococcus at delivery and prolonged rupture 
of membranes. Group B streptococcus infection may cause premature delivery, 
stillbirth, chorioamnionitis, group B streptococcus bacteriuria (Suara et al., 1998; 
Law., et al., 2005). Ethnicity, maternal age and parity, marital status, education and 
smoking are factors that have been reported to influence the prevalence of 
colonization, with studies that was done in the United States, have shown that 
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occupation, black race, Hispanic ethnicity, age, high parity and high body mass index 
might be associated with group B streptococcus colonization in pregnancy (Stapleton 
et al., 2005). 
Group B streptococcus possess genotypic and phenotypic markers which are 
important in epidemiological settings (Doran and Nizet, 2004; Mavenyengwa et al., 
2009). Group B streptococcus is divided into nine serotypes (Ia, Ib, and II-VIII) 
according to distinct capsular polysaccharides, and serotype IX was identified in 
2007, which appears to be mostly related to serotype Ib, although its cps gene 
cluster is related to those of serotype V, Ia and IV (Slotved et al., 2007). The specific 
capsular polysaccharides are composed of different arrangements of glucose, 
galactose, N-acetylglucosamine and sialic acid (Doran and Nizet, 2004; Cieslewicz 
et al., 2005). Almost all serotypes of group B streptococcus have been associated 
with invasive disease in neonates, group B streptococcus capsular type III is the 
most frequent isolate and cause majority of late onset disease and meningitis (Polin 
et al., 1982). 
Common serotypes reported in South Africa are Ia, Ib, and III.  Serotype III was 
reported as being the most pathogenic strain (Madzivhandila et al., 2011). A recent 
systematic review and meta-analysis of group B streptococcus found that in low and 
high-income countries, the main serotypes are Ia, Ib, II, III and V, thus a vaccine 
including these serotypes could prevent invasive group B streptococcus (Edmond et 
al., 2012). 
To gain insight into epidemiology and the phylogeny of the organism such as group 
B streptococcus typing method is performed. Molecular typing methods have several 
advantages over serotyping method, among the generation of more ambiguous 
results and they bypass the problem of immunological cross-reactivity. More 
advanced molecular methods such pulse-field gel electrophoresis and multilocus 
sequence typing (MLST) have the ability to differentiate strain collections into many 
types (Radtke, 2012) 
Traditionally, descriptive epidemiology of group B streptococcus has relied on 
capsular serotyping or genetic typing; this includes that determined by pulse -field 
gel electrophoresis, and multilocus sequence typing (Jones et al., 2003; Tien et al., 
2011). In order to compare experiments, it is required that DNA sequencing and 
analysis are performed using portable standard, one such standard is MLST; a 
nucleotide sequence based approach for the unambiguous characterisation of 
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isolates of bacteria and other organisms and is particularly suitable for 
epidemiological studies because it provides data that can be compared easily 
between laboratories over the internet (Jones et al., 2003). The aim of MLST is to 
provide a portable, accurate, and highly discriminating typing system that can be 
used for most bacteria and some other organisms. It is envisaged that this approach 
will be particularly helpful for the typing of bacterial pathogens. Therefore; the study 
aimed to investigate the epidemiology of group B streptococcus colonization among 
pregnant women and to characterize group B streptococcus isolates by multilocus 
sequence typing at Dr George Mukhari Academic Hospital, Pretoria. 
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1.2. Problem statement 
Bacterial infections are frequently the direct or principal underlying cause of human 
neonatal deaths. The group B streptococcus is regarded as the dominant group of 
gram-positive bacteria that are responsible for severe or life threatening infections 
(Lachenauer et al., 2002). The epidemiology of group B streptococcus has not been 
well studied in South Africa. Recent studies on maternal factors associated with high 
attack rates for early-onset group B streptococcus disease have reported black race, 
history of previous miscarriages, young adults of 20 years of age and preterm 
delivery as risk factors (Farley, 2001; Batalis et al., 2007). Traditional and molecular 
typing schemes for the characterization of pathogenic microorganisms are poorly 
portable because their index variation that is difficult to compare among laboratories 
and some less frequently used molecular typing methods involves indirect 
characterization of gene alleles through electrophoresis of gene products.  
1.3. Objectives of the study 
1.3.1. Main objective 
To investigate the epidemiology of group B streptococcus colonization among 
pregnant women and to characterize group B streptococcus isolates by multilocus 
sequence typing at Dr George Mukhari Academic Hospital, Pretoria. 
1.3.2. Specific objectives 
 To estimate the group B streptococcus colonization among pregnant 
women and their neonates. 
 To establish sensitivity of different media in group B streptococcus 
detection. 
 To characterize group B streptococcus serotype isolates using 
multilocus sequence typing. 
1.4. Motivation of the study 
This study was to provide baseline information on the prevalence of group B 
streptococcus. Data on the rate of group B streptococcus colonization; these will be 
useful in the development of guidelines for screening of group B streptococcus in 
order to be able to manage the patients. MLST is one of the most reliable tools for 
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group B streptococcus typing, with sufficient discrimination for use in epidemiology 
and unambiguous characterization of isolates. Sequence data can be compared 
readily between laboratories, such that a typing method based on the sequences of 
gene fragments from a number of different housekeeping loci is fully portable. Data 
stored in a single expanding central multilocus sequence database can be 
interrogated electronically through the internet to produce the powerful resource for 
global epidemiology (Jones et al., 2003).   
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CHAPTER 2 
2. LITERATURE REVIEW 
2.1. Group B streptococcus 
Streptococcus agalactiae is characterized by the presence of group B Lancefield 
antigens and gram positive facultative anaerobic diplococcus of genus streptococcus 
with an ultrastructure similar to other gram positive cocci, which can grow on a 
variety of microbiologic media (Baker et al., 1977; Edwards and Baker, 2001). When 
cultured on sheep blood agar, they appear as glistening grey-white colonies with a 
narrow zone of beta haemolysis larger than Streptococcus pyogenes, usually found 
on gram stain to be arranged in chains, frequently pigmented after anaerobic 
incubation on Columbia agar and grow in the presence of bile on MacConkey agar 
(Mims et al., 2004).  
Culture of group B streptococcus is routinely performed on agar supplemented with 
sheep’s blood, and colonies are detected by the breakdown of red blood cells, 
producing a characteristic zone of hemolysis, termed beta hemolysis (Schrag et al., 
2002).  The presence of group B streptococcus may be confirmed by performing 
Gram staining, CAMP (Christie, Atkins, and Munch-Peterson) testing, or typing via 
an agglutinin reaction on selected beta haemolytic colonies (Verani et al., 2010). 
This is often labour intensive, and in cases in which the patient’s sample contains 
many different species, beta hemolysis may be missed (Schwartz et al., 2012; Adler 
et al., 2008).There is a risk that samples may be overgrown with competing 
organisms, such as Proteus or Enterococcus, and false negatives are not 
uncommon. When hemolysis is identified, follow-up testing is often required to 
prevent a false positive from being reported (Bou et al., 2005). While culture 
continues to be regarded as the gold standard, it is labour intensive and is not 
without shortcomings (Faro et al., 2013). 
Group B streptococcus, is a very invasive encapsulated organism capable of 
producing severe disease in immunocompromised hosts. This pathogen can be 
recovered from sterile sites on a selective blood agar, however there is a standard 
method to isolate Group B streptococcus from genital or rectal sites, where a 
selective broth medium (Todd-Hewitt or Lim broth) that contains antibiotics such as 
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nalidixic acid, colistin or gentamicin to inhibit other bacteria (Baker et al., 1977). This 
bacterium has group B cell wall antigen, which is composed of rhamnose, galactose 
and N-acetylglucosamine. Group B streptococcus is able to hydrolyze sodium 
hippurate, is resistant to bacitracin, and is sensitive to bile; therefore, these bacteria 
will lyse in the presence of bile (Shen et al., 2001). 
Group B streptococcus isolation from blood, cerebrospinal fluid (CSF), another 
usually sterile site, or a site of focal suppuration is only means by which the 
diagnosis of invasive infection can be documented. Detection of group B 
streptococcus antigen in serum or CFS using methods such as latex agglutination 
may be established as a presumptive diagnosis. Antigen tests have poor sensitivity 
and variable specificity, with the results that are infrequently useful in diagnosis 
establishment, antigen testing of urine is not recommended (Forbes et al., 2007).  
2.2. Group B Streptococcus colonization 
Group B streptococcus is part of the normal flora of the gut and genital tract in 
humans. About 16-40% of healthy adults are asymptomatically colonized with group 
B streptococcus in human genitals (Brimil et al., 2006). When compared to group A 
streptococcus and Streptococcus pneumonia, however, little is known about the 
pathogenesis, natural history and transmission dynamics of group B streptococcus 
(Manning, 2003). Group B streptococcus can colonize vaginal and/ or rectal sites of 
women without showing any symptoms, from which can be transferred to the 
newborn babies during parturition, since group B streptococcus exist as normal flora 
in genitourinary and gastrointestinal tracts (Shen et al., 2001). Accordingly, 
colonization is rare in neonates delivered by caesarean section before the onset of 
labour (Law et al., 2005). 
After the establishment of neonate colonization, the systematic infection may occur 
through the umbilical cord, respiratory tract or skin abrasions. The ascent of 
organisms to the foetus from the mother’s genital tract through ruptured or intact 
membranes, with aspiration or ingestion of infected amniotic fluid by the foetus is a 
second important source of infection occurring before birth (Law et al., 2005). The 
study indicated that, African women were at a higher risk (29%) as compared to 
Europeans and Asian women, of which were at lower risk (13%) for group B 
streptococcus carriage (Valkenburg-van den Berg et al., 2006). A study done in 
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Malawi showed lower colonization rate, with the overall colonization rate of group B 
streptococcus to be 16.5 % (Dzowela et al., 2005) as compared with the three 
separate studies in Zimbabwe were group B streptococcus colonization rate was 
shown to be 20 %, 31 %, and 32% (Mason et al., 1989; Stoll and Schuchat., 1998). 
A study from Maputo, Mozambique indicated low prevalence of group B 
streptococcus colonization among pregnant women between 35 and 37 weeks of 
pregnancy (1.8%). The method used was a rectovaginal swab which was taken from 
women between 35 and 37 weeks of pregnancy who visited the clinic for antenatal 
consultation (De Steenwinkel et al., 2008).  
 
The colonization rates have been found to vary by geographic areas, term of 
pregnancy and age group. In another study conducted in Zimbabwe by 
Mavenyengwa et al., (2006); mother cumulative colonization rate after sampling 
three times was found to be significantly higher in the rural areas (60%) as compared 
to the urban areas (46%). Group B streptococcus colonization persistence showed to 
be more in rural (48%) than in urban women (12%). Baby colonization was also 
shown to be more in the rural (23%) than in urban area (5%). The prevalence of 
group B streptococcus colonization during pregnancy is variable; in one study, 
among women who had positive GBS cultures between 26 and 28 weeks of 
gestation, only 65% remained colonized at term, while 8% of those with negative 
prenatal cultures were positive for GBS at term (Shet and Ferrieri, 2004).  
 
The study in Hong-Kong showed the prevalence of group B Streptococcus 
colonisation in antenatal population was found to be 10.4%. The majority of carriers 
were identified by low vaginal swabs (78%), while high vaginal swabs and rectal 
swabs only identified 31% and 30% of the carriers, respectively. Pregnant women, 
who work outside home, yielded a higher carrier rate than housewives (21% vs10%). 
There was no increase in preterm delivery rate in group B Streptococcus carriers 
indicated in this study (Tsui et al., 2009).  
The rate of group B streptococcus colonization in the vagina and/or rectum among 
pregnant women varies with ethnic group, geographic area and age (Shet and 
Ferrieri, 2004). Group B streptococcus colonization may be intermittent during 
pregnancy. A positive test for group B streptococcus in pregnant women might 
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therefore be a poor predictor for colonization at delivery. However, few studies have 
reported results of repeated tests during pregnancy. Such a study has recently been 
conducted in Denmark. In the study conducted in Denmark, group B streptococcus 
colonization in a cohort of 77 women was relatively stable during pregnancy and up 
to a period of a year after delivery. In African women, little is known of group B 
streptococcus colonization during pregnancy as well as the predictive value of 
colonization at different stages for colonization of group B streptococcus at delivery 
(Mavenyengwa et al., 2010). 
2.3. Group B Streptococcus prevalence 
Until recently, Group B streptococcus was infrequently reported in the developing 
world. Yet the prevalence of maternal carriage of group B streptococcus in 
developing countries, including the populations in tropical Africa, is similar to the 
identified populations in the United States (Stoll and Schuchat., 1998; Dawudo et al., 
1983). Studies from Kenya ( Berkley et al., 2005; English et al., 2003 ; Laving et al., 
2003), South Africa (Bomela et al., 2001; Madhi et al., 2003), Zimbabwe (Nathoo et 
al.,1990) and Malawi (Milledge et al.,2005) suggested that group B streptococcus is 
emerging as an important cause of neonatal sepsis in Africa. Studies done in South 
Africa have also showed that the burden of invasive GBS disease in South Africa is 
greater than in developed countries (Madhi et al., 2003). The prevalence among 
black pregnant women in South Africa and United States has shown to be higher 
than in women of other racial groups. Most documented data on group B 
streptococcus has come from Europe and North America and to date only Zimbabwe 
and Malawi in Africa have active research programme on group B streptococcus 
colonization and burden diseases (Moyo, et al., 2002; Dzowela et al., 2005).  
 
The prevalence may differ due to culture technique differences, the location 
differences and number of sites cultured and the population studied. Women of 
Caribbean origin, and black women, previously were reported to be at greater risk of 
colonization than those of Mexican origin and white women, which make a 
suggestion of a role for ethnic or genetic factors (Valkenburg-van den Berg, et al., 
2006). Prevalence of group B streptococcus is 16.5% in Malawi (Dzowela et al., 
2005), 19.0% in Ivory coast, 20.0% in Nigeria, 22% in Gambia (Stoll and Schuchat, 
1998) and 32% in Zimbabwe (Moyo et al, 2002).  
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The incidence among black American infants increased during the years 2003-2005 
(70%), whilst incidence rates among white Americans infants decreased. In the year 
2005, among black infants in the United States, the rate of early onset group B 
streptococcus disease infection was 0.84 per 1000 live births compared to 0.24 per 
1000 deliveries in white infants (Pulver et al., 2009). Geographic variations in early 
onset group B streptococcus disease infection rates have also been noted, ranging 
from 0.53 cases per 1000 live births in Tennessee to 0.14 in Oregon (CDC, 2002). 
Generally in the United States prior to the introduction of intrapartum prophylaxis the 
overall incidence of neonatal group B streptococcus infections were approximately 2 
per 1000 live births (Baker and Edwards, 2001).  
 
In South Africa, during the period 1997 to 1999, the burden of neonatal group B 
streptococcus was 2, 06 cases/1000 lives births and 1case/1000 live births for early 
and the late onset disease respectively (Madhi et al., 2003), and in Netherlands, the 
incidence of early onset group B streptococcus disease in the period from 1997-1998 
was estimated at 1.9 per 1000 live births, with a fatality case rate of 5% (Valkenburg-
van den Berg., et al., 2006). In the study conducted to determine the prevalence of 
group B streptococcus and to identify group B streptococcus colonisation risk factors 
in a multicultural population of pregnant women in Netherlands, it was found that 
carrier rate of group B streptococcus in late pregnancy was 21% (Valkenburg-van 
den Berg et al., 2006).  
 
Previous studies suggested that maternal rectal colonization may be the important 
acquisition source of group B streptococcus in newborns. The rectal swabs exclusion 
to detect group B streptococcus colonization may compromise the sensitivity in 
group B streptococcus colonization detection (Stoll and Schuchat, 1998). Previous 
research studies reported that the sensitivity of detecting group B streptococcus 
colonization in pregnant women by undertaking both vaginal swabs and rectal is 
higher (18, 5 -51%) when compared to taking only vaginal swabs (Dzowela et al., 
2005) since both the vaginal and rectal flora contain numerous microorganisms. The 
use of selective enrichment broth is recommended to maximise the isolation of group 
B streptococcus and to avoid the overgrowth of the other microorganism (Ferrieri et 
al., 1977). 
11 
 
When agar plate is used instead of enrichment broth, many women who are group B 
streptococcus carriers give false-negative culture results. This was proved by 
(Ferrieri et al., 1977) and Kubota (2002) who did not use selective culture medium 
and only found the prevalence rates of 5.6% and 11.4%, whereas with studies that 
used selective medium reported rates of 19.8% and 18.6% (Madzivhandila et al., 
2011;Valkenburg-van den Berg, et al., 2006).  
2.4. Group B streptococcus disease 
Group B streptococcus, was originally known for causing bovine mastitis and was 
not demonstrated to be a human pathogen until the year 1938, after description of 
three patients with fatal puerperal sepsis (Fry, 1938). The bacteria remained 
unknown to most clinicians until the years around 1970s, when the observations of 
dramatic increase of group B streptococcus septicaemia and meningitis in neonates 
occurred in different parts of the world (Law et al., 2005).  
2.5. Disease in newborn babies 
Group B streptococcus is known as the important leading neonatal pathogen 
worldwide that causes morbidity and mortality in neonates (Baker, 2000; Beitune et 
al., 2005). Despite the decrease in the last decades, early onset group B 
streptococcus disease remains a serious neonatal condition, which may cause a 
serious neurological damage (Valkenburg-van den Berg et al., 2006). These bacteria 
cause invasive infections such as, meningitis, pneumonia and sepsis in newborn 
babies (Gonza´lez-Outeirin˜o et al; 2004; McKenna and Iams, 1998). 
Group B streptococcus can pass through the cervix without causing serious 
cervicitis, and cross-intact amniotic fluid causing amnionitic thereby infecting the 
foetus in the uterus (Dzowela et al., 2005). Most of neonatal group B streptococcus 
infections occur during gestation and at delivery due to the failure to produce and 
transmit cross-placental sufficient serum antibody against group B streptococcus by 
the mother (Suara et al., 1998), Group B streptococcus pathogen is the most prevalent 
infection in the first week of life, presenting in two forms: early-onset and late-onset. 
Early onset infection will flare-up in the first week and mainly (90%) in the first 12 
hours (Javanmanesh and Eshraghi, 2013). Late-onset disease (LOD) occurs after 
the first week until 3 months and accounts for most meningitis cases and deaths 
(Dzowela et al., 2005).  
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2.5.1. Early onset disease 
The group B streptococcus that causes early-onset infection is usually due to 
transmission from a mother to the baby due to amniotic fluid infection or from the 
birth canal of a colonized mother. Of all infants born of these women who are 
colonized with group B streptococcus, 1 to 2% will develop early onset invasive 
disease (Matlova et al., 2004). The incidence of early-onset disease is about 10 
times higher in premature than in term neonates (Boyer et al., 1983). The newborn 
will present with symptoms such as breathing problems, blood pressure and heart 
rate instability, gastro-intestinal and urinary system disturbances, sepsis, pneumonia 
and meningitis (Javanmanesh and Eshraghi, 2013). 
2.5.2. Late-onset disease 
Late-onset group B streptococcus, results from contamination through direct contact 
with other colonized individuals in the community. The bacterium causes pneumonia, 
bacterial sepsis, and meningitis in most of newborn babies (Beal and Dancer, 2006; 
Schrag et al., 2000; Javanmanesh and Eshraghi, 2013). Despite early antimicrobial 
treatment in neonatal intensive care, up to 10% neonatal invasive group B 
streptococcus infections are lethal and about 25-35% of surviving infants with 
meningitis experience permanent neurological sequelae (Baker, 2000).  
2.6. Group B streptococcus disease in pregnant women 
Group B streptococcus is known as the important leading neonatal pathogen 
worldwide that causes maternal infections (Baker, 2000; Beitune et al., 2005).The 
mortality rate from invasive group B streptococcus infection in pregnant women is 
extremely low. Group B streptococcus colonised pregnant women, have high risk 
factors associated with mother to child transmission including: prolonged rapture of 
membranes, maternal pyrexia during labour and preterm delivery (Schrag et al, 
2000). These bacteria can cause chorioamnionitis, urinary tract infection and wound 
infection in pregnant women (Gonza´lez-Outeirin˜o et al., 2004; McKenna and Iams, 
1998). 
Group B streptococcus is able to infiltrate the amnionitic cavity even if the 
membranes are intact or not, and infect the foetus through lung epithelium (Beal and 
Dancer, 2006; Schrag et al., 2000). Culture collection between 35 and 37 weeks’ 
gestation is recommended to improve the sensitivity and specificity of the 
identification of women who are colonised at the time of delivery (Valkenburg-van 
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den Berg et al., 2006). In the study performed by Boyer et al., (1983), it was 
observed that women at parturition with negative vaginal but positive rectal cultures 
had a group B streptococcus vertical transmission rate of 17% to their new born 
babies.    
2.7. Group B streptococcus disease in adults 
Black race is associated with an increased risk of group B streptococcus infection in 
most adults and this reflects socio-economic factors (Schrag et al., 2000). The 
incidence of disease among non-pregnant adults, particularly among adult with 
underlying conditions such as diabetes mellitus, HIV-AIDS and malignant diseases, 
has increased over the past decade. In non-pregnant adults with underlying medical 
conditions, group B streptococcus can cause urosepsis, pneumonia, as well as a 
skin and soft tissue infections (Farley, 2001).  
2.8. Group B streptococcus antigens 
Group B streptococcus; a Gram-positive coccus surrounded by a thick cell wall that 
acts as an exoskeleton to guarantee resistance to mechanical stresses and 
maintenance of cell shape. Understanding the organization and the functioning of the 
cell wall is very important as this cellular compartment is essential to bacterial 
physiology and the target of many antibiotics. Originally, Rebecca Lancefield defined 
two cell wall carbohydrate antigens in group B streptococcus: the group B-specific 
antigen common to all strains and the capsular antigen which currently defines ten 
different serotypes (Ia, Ib, II to IX) (Lancefield, 1934; Slotved et al., 2007). The 
complex multiantennary structure of group B carbohydrate based on arrangement of 
four different oligonucleotides (rhamnose, galactose, N-acetylglucosamine and 
gluticol) was solved in a series of seminal studies at the end of 1980s (Michon et al., 
1987; Michon et al., 1988).  The capsular polysaccharide and the group B 
carbohydrate were shown to be covalently bound to the peptidoglycan at separate 
sites (N-acetylglucosamine and N-acetylmuramic acid respectively). The type V 
capsular polysaccharide has a unique repeating unit structure consisting of a 
trisaccharide backbone with two distinct side chains. Antibodies against the serotype 
V capsule do not cross react with other group B streptococcus capsular types and 
appear to recognize an epitope which is not as heavily dependent on the presence of 
terminal side chain of  salic acid residue as that of types Ia, II, and III GBS 
polysaccharides (Baker et al., 2003). 
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2.9. Group B streptococcus capsular types 
Group B streptococcus is one of many serologically distinct species within the genus 
streptococcus, however; Group B streptococcus is identified based on the presence 
of a polysaccharide type-specific antigen that is common to all Group B 
streptococcus strains determined by serological testing (Harrison et al., 1998).  This 
common group B cell wall antigen are composed of rhamnose, galactose, and N-
acetylglucosamine (Bhushan et al., 1998). 
Therefore, group B streptococcus capsular polysaccharide is composed of 
pentasaccharide repeating units of N-acetylglucosamine, N-acetylneuraminic acid, 
glucose and galactose. Maintaining the conformation of the antigenic epitope of 
group B streptococcus the N-acetylneuraminic acid play the critical role. High 
specific binding of antibody to the group B streptococcus type III capsular 
polysaccharide is dependent on negatively charged N-acetylneuraminic acid’s 
presence positioned as the terminal saccharine of the disaccharide side chain 
(Paoletti and Johnson, 1995).  
The polysaccharide capsule, which is the basis for serotyping, is the major known 
virulence factor among group B streptococcus, almost all group B streptococcus 
isolated from invasive cases are encapsulated (Manning et al., 2003). The 
differentiation of group B streptococcus into types based on capsular 
polysaccharides antigens has provided a valuable tool for defining the epidemiology 
of human infection. There are nine serotypes identified based on their capsular 
polysaccharide structure labelled Ia, Ib, II,III,IV,VI.VII,VIII and IX that were isolated 
from human and these are used as epidemiologic markers (Slotved et al., 2007).  
2.10. Group B streptococcus capsular types distribution 
Some capsular types are geographically specific, for example, capsular type III that 
is found almost exclusively in Japan. Capsular polysaccharides dominate the surface 
of some bacteria and are the major target of the immune system’s attack, which 
primarily involves antibodies, complement, and phagocytic cells (Guttormsen et al., 
2002). Group B streptococcus capsule primary function is thought to be protection of 
the organism by downregulating the complement system and prevention from 
phagocytosis by the host immune system (Burnham and Tyrell, 2003). Capsular 
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polysaccharide has been shown to elicit type specific antibodies against group B 
streptococcus, which protects against invasive infections (Lancefield et al., 1975).  
Strains of four classical serotype; Ia, Ib, II and III are of particular importance 
because they have been reported to account for many of group B streptococcus 
infections in infants in most cases of neonatal meningitis (Harrison et al., 1998). 
Although all group B streptococcus serotypes may cause infections, type Ia, II and III 
form the majority of Group B streptococcus disease (Harrison et al., 1998). Reports 
from diverse geographic regions documented type V as a frequent cause of 
colonization and invasive disease, first in neonates then later in adults (Blumberg et 
al., 1996; Davies et al., 2001). The emergence of type V is not due to a single clone, 
but most type V isolates do have one pulse field gel electrophoresis pattern that has 
been present in the united states since 1975 ( Elliot et al.,1998). 
Type Ia has increased in prevalence and corresponding decline has occurred in type 
II strains causing perinatal disease (Zaleznik et al., 2000). Group B streptococcus 
type III polysaccharide capsule as suggested by immunological and epidemiological 
data is a major factor contributing to the virulence of the organism, and is more 
invasive than other serotypes, and this may be due to the response of specific 
maternal antibody against the bacterium strain (Capsular type III) (Davies et al., 
2001). Group B streptococcus capsular type III cause significant percentage of early 
onset disease in newborns and cause majority of late onset disease in newborns 
which manifest as meningitis and causes most of the mortality rate (Takahashi et al., 
1999). 
Serotype III has been studied in the greatest detail, primarily because of its 
association with invasive neonatal disease. Serotypes III are more resistant to 
opsonophygocytic killing by interfering with host complement factor C3b and are 
more virulent. The sialic acid component of the capsule inhibits the alternative 
pathway of component by preventing deposition of active C3 on the surface of group 
B streptococcus. Eventually if C3 does deposit, conversion of C3b to I C3b on the 
bacterial surface is promoted by a capsule, resulting in the organism being resistant 
to uptake and killing by neutrophils (Burnham and Tyrell, 2003). Types VI, VII, VIII 
and IX rarely cause human disease in United States or United Kingdom, but in Japan 
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types VI and VIII are the predominant strains causing disease in neonates and 
healthy Japanese women (Lanchenauer et al., 1999). 
Identification of group B streptococcus is based on the group B specific cell wall 
antigens common to all strains. Methods of which each uses hyperimmune group 
specific antisera have been developed to detect the group B streptococcus antigen: 
enzyme-linked immunosorbent assay (ELISA), counter current immunofluorescence, 
staphylococcal agglutination and latex agglutination. Latex agglutination method is 
widely used due to commercial availability and simplicity. The suggested adequate 
method for the differentiation of group B streptococcus from other β-haemolytic 
serogroups of streptococci is the combination of the CAMP test with bacitracin 
sensitivity and the esculin reaction (Facklam et al., 1979). 
2.11. Expressed virulence factors 
Many group B streptococcus researchers have performed an evaluation on the 
expression of specific virulence factors in vitro (Beta-haemolysin, CAMP factor, 
oligopepetidase, hylauronate lyase and carbohydrate toxin CM101) or in animal 
models, which has contributed greatly to understanding of disease pathogenesis 
(Manning, 2003). Group B streptococcus pathobiology, indicates that the bacterium 
must encounter a number of diverse cell types such as macrophages, epithelial cells 
and endothelial cells during the process of invasive disease. So for this bacterium to 
overcome these defensive barriers and survive in the host, group B streptococcus 
must possess a variety of virulence factors (Burnham and Tyrrell, 2003).  
 Some virulence factors are only expressed in the host and not in the laboratory, thus 
the expression levels measured may not accurately reflect in vivo levels. This 
variable expression often decreases the reproducibility of the results. Like many 
pathogenic bacteria, group B streptococcus encodes a myriad of virulence factors 
that are critical for its ability to cause disease. There are GBS virulence factors, such 
as the pore-forming toxins and the sialic acid-rich capsular polysaccharide (CPS) 
(Manning, 2003), capsule, lipoteichoic acid, camp factor, beta haemolysin, 
hylauronate lyase, oligopepetidase activity, C- protein, superoxide dismutase, C5a 
peptidase, penicillin binding protein, induction of apoptosis in macrophage and two 
component regulatory system (Burnham and Tyrell., 2003).  
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2.12. Group B streptococcus infection prevention efforts 
Based on theory, early-onset and late-onset group B streptococcal disease could be 
prevented only if susceptible hosts were not exposed to the microorganism or if 
exposure occurred in the setting of protective immunity. Several approaches to 
prevention have been advocated; conceptually, these are directed at eliminating 
exposure or enhancing host resistance by chemoprophylaxis or immunoprophylaxis. 
Both strategies have limitations with respect to implementation, but could be targeted 
for the prevention of maternal and neonatal infections and are theoretically 
achievable (Baker, 1990). 
Different strategies for identification of high risk mothers and infants and provision of 
intrapartum prophylaxis may reduce the rate of neonatal sepsis, though they are 
unlikely to eliminate the problem (Shet and Ferrieri, 2004). Limitations to the use of 
intrapartum antibiotics include the emergence of antibiotic-resistant group B 
streptococcus and ineffectiveness in preventing late-onset disease. Intrapartum 
vaginal and newborn chlorhexidine washes have not prevented sepsis in 
independent trials in South Africa and Pakistan, leaving resource-poor countries with 
no feasible alternative to vaccination (Cutland et al., 2009; Saleem et al., 2010), to 
elicit protective levels of antibodies in mothers (Lin et al., 2001). Active maternal 
immunization may prevent peripartum maternal and neonatal disease by 
transplacental transfer of protective IgG antibodies. Transport across the placenta is 
limited before 34 weeks of gestation, so preterm babies are less well protected 
(Phares et al., 2008; Madhi et al., 2003).  
From the nine recognised serotypes of GBS:  a 4-valent vaccine (types Ia, Ib, III, V) 
would cover an estimated 85% of cases on the basis of distributions of invasive 
disease serotypes in industrialised countries and South Africa (Phares et al., 2008; 
Madhi et al., 2003). Vaccines that produce antibodies against the group B 
streptococcus capsule have been made available, and would hopefully prevent both 
early and late-onset neonatal infection. Glycoconjugate vaccines with type specific 
polysaccharide covalently linked to tetanus toxoid have shown to be protective in 
experimental animals and glycoconjugate vaccine composed of the type III 
polysaccharide and C protein could in theory protect against infection (Beal and 
Dancer, 2006). 
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The evaluation of investigational group B streptococcus vaccines, however, will require 
large sample sizes, because of reduced incidence of disease that has resulted from 
the use of intrapartum antibiotics, and would take a long time to evaluate efficacy if 
the vaccine were administered to women before pregnancy. Evaluating the safety of 
administering the vaccine to pregnant women would be difficult, due to the incidence 
of birth defects and again their occurrence with vaccination would be difficult to 
evaluate (Lin et al., 2001). Robins et al., 1995 proposed that licensure be granted for 
group B streptococcus vaccines that induce protective levels of group B streptococcus 
type-specific antibody without efficacy trials in order to avoid the problems. To 
simplify the licensure of group B streptococcus vaccines, Lin et al., (2001) conducted a 
seroepidemiological study to estimate the protective antibody level, as measured by 
a standardized ELISA. 
Group B streptococcal conjugate vaccine formulations for group B streptococcus 
have undergone Phase1 and Phase 2 trials, including one small trial of maternal 
vaccination in the USA that showed safety and sustained functional antibody 
responses in mothers and infants two months after delivery (Baker et al., 2003). 
Phase 2 trials with serotype III conjugate showed moderate protection against 
acquisition of serotype III group B streptococcus in the vagina and rectum (Hillier et 
al., 2009). 
2.13. Epidemiological typing 
Serologic or molecular typing of capsular Polysaccharides and surface proteins 
distinguish between isolates of a microbial population, but may be insufficient in 
detecting virulent clones in a local outbreak and are also inadequate for evolutionary 
studies. Molecular typing methods may identify clones or closely related strains 
recovered from an outbreak, describe the population in an area and show the 
relatedness of isolates from different geographic areas to common ancestors. 
Several methods of molecular typing have been developed; the two most widely 
used methods in epidemiological studies of GBS at present are pulsed-field gel 
electrophoresis (PFGE) and multilocus sequence typing (MLST). 
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2.14. Multilocus sequence typing  
To study the epidemiology of group B streptococcus, molecular methods such as 
multilocus sequence typing are used (Delannoy et al., 2013). Data from MLST can 
be used to investigate evolutionary relationships among bacteria. While PFGE is a 
gel-based analysis and dependent on visual interpretation, MLST is a more 
unambiguous genotyping method and sequence data are transferable between 
laboratories. MLST consisted of the amplification by PCR and sequencing of seven 
housekeeping genes (Figure 2.1) (alcohol dehydrogenase (adhP), phenylalanyl 
tRNA synthetase (pheS), amino acid transporter (atr), glutamine synthetase (glnA), 
serine dehydratase (sdhA), glucose kinase (glcK), and transketolase (tkt)), these 
method provides the sequences of 450-500 base pairs from fragments of the above 
listed seven “housekeeping genes encoding central metabolic enzymes in the 
organism (Jones et al., 2003) and has been used successfully to type strains and 
investigate the population structure of a number of human bacterial pathogens, 
including Neisseria meningitidis and Streptococcus pneumoniae. (Jones et al., 2003; 
Delannoy et al., 2013). For each housekeeping gene, the nucleotide sequences may 
vary. The variants of the genes are assigned as alleles, and the combination of 
alleles at each of the seven loci represent an allelic profile which unambiguously 
defines the sequence type (ST) of each isolate (Maiden, 2006; Maiden et al., 1998).  
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Figure 2.1. Schematic map of the group B streptococcus genome. Genes used in 
conventional MLST are shown in green adapted from (Sorensen et al., 2010). 
 
In MLST, the number of nucleotide differences between alleles is ignored, and 
sequences are given different allele numbers whether they differ at a single 
nucleotide site or at many sites (Maiden et al., 1998). The rationale for this is that a 
single genetic event resulting in a new allele can occur by a point mutation (altering 
only a single nucleotide site), or by a recombinational replacement that will often 
change multiple sites. Weighting according to the number of nucleotide differences 
between alleles would imply that the latter allele was more distantly related to the 
original allele than the former, which would be true if all nucleotide changes occurred 
by mutation, but not if the changes occurred by a recombinational replacement 
(Maiden,2006; Maiden et al.,1998).  
 
The clonal structure of the group B streptococcus population has been demonstrated 
by a variety of techniques, including multilocus enzyme electrophoresis, restriction 
endonuclease digest patterns of chromosomal DNA, pulsed-field gel electrophoresis 
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and gene analysis, and, most recently, by multilocus sequence typing ( Cooper and 
Feil, 2004).  
 
These studies have demonstrated that serotype III group B streptococcus associated 
with human disease derive largely from two distinct phylogenetic lineages. Although 
these two lineages can be identified by any of these techniques, MLST has the 
advantage of reproducibility and has been shown to correlate with the other 
techniques and thus has emerged as the standard for delineating the clonal 
population of group B streptococcus (Delannoy et al., 2013). MLST is particularly 
suitable for epidemiological studies because it provides data that can easily be 
compared between laboratories over the Internet (Jones et al., 2003), and is an 
important tool for molecular epidemiology because the MLST databases for 
individual pathogen species currently cover far more isolates than have been 
characterized based on whole genome sequencing. Similarly, isolates that have 
been characterized by three-set genotyping still outnumber isolates that have been 
characterized by whole genome sequencing, thus providing a less detailed but 
broader frame of reference than offered by whole genome sequences (Delannoy et 
al., 2013). 
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CHAPTER 3 
3. MATERIALS AND METHODOLOGY 
3.1. Study Area 
The study was conducted at Dr. George Mukhari Academic Hospital in Ga-Rankuwa, 
Gauteng province; Pretoria, which services the city of Tshwane municipality. The 
hospital serves as the teaching hospital for University of Limpopo (Medunsa 
campus). Ga-Rankuwa has mixed population comprising of various African tribal 
groups. The hospital’s antenatal clinic and paediatric outpatient department serve 
the immediate surrounding areas and distant areas such as Limpopo and North 
West provinces. 
3.2. Study design and population 
This was a descriptive, prospective study, where pregnant patients presenting to the 
antenatal care (ANC) clinic at Dr. George Mukhari Academic Hospital from 4-40 
weeks were recruited to form a cohort group. After signing an informed consent 
(Appendix A), samples were collected to investigate for Streptococcus agalactiae. 
Those with positive results were managed according to the departmental policy and 
their hospital file of record was tagged such that the Registrar on call can identify 
them as study participants. The colonised parturient women were followed up, to 
repeat the samples when they present in labour. Screening samples were also taken 
from the babies immediately after delivery. A research nurse was hired to assist with 
recruitment and follow-up of the cohort group. 
3.3. Sample size 
The prevalence of Streptococcus agalactiae in South Africa is estimated at 10%, as 
such a prevalence of 10% was used to calculate sample size. Based on estimation 
of 30 pregnant women seen at the ANC per day, the estimated population was 20 
000 women over a two year period. At an expected frequency of 10%, confidence 
level of 95% and a margin of error of 5% sample size were calculated to be 138 
using EpiInfo v6. Due to the challenges of retention which were expected with a 
cohort, a sample size was increased to 200 to accommodate for lost to follow-up and 
home deliveries. An additional 100 pregnant women whom were not seen at ANC 
and only presenting at labour were also be included in the study to make sample 
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size to a total of 300. To obtain valid and statistically relevant results, a clutch size of 
300 samples was finally considered. Sampling took place over a period of a year. 
Due to lack of cooperation in the clinic and loss of participants, sample size was 
increased to a total of 413. 
3.4. Sampling 
Every pregnant woman (4-40 weeks gestation) seen at the antenatal clinic (ANC) 
was recruited until sample size of 413 was reached. This formed the cohort that was 
followed at delivery and post-delivery including their babies.  
3.4.1. Inclusion criteria 
 Consented pregnant women, who attended antenatal clinic at Dr George 
Mukhari Academic Hospital from 4 to 40 weeks gestations to form a cohort 
aged 18 years and above was included in the study. 
3. 4.2. Exclusion criteria 
 Pregnant women who did not sign the consent form. 
 Pregnant women whom had been on antibiotics for the past 2 weeks.  
 Very sickly pregnant women 
3.5. Methods 
3.5.1. Data collection by questionnaire (Appendix B) 
A questionnaire was designed and used to collect information regarding socio-
economic data, obstetric history and the current pregnancy from each of the study 
participants at recruitment. Data from the hospital and clinic records included 
information routinely collected at the time of delivery from the mother and the 
neonates. Information of socio-economic characteristics (level of education, 
employment and marital status), demographic data and obstetric history (parity, 
miscarriages, stillbirths and any serious illness or vaginal discharge requiring 
treatment during pregnancy) were collected by a questionnaire at recruitment.  
3.5.2. Specimen collections and processing 
Collection of specimens was carried out for a period of a year, after permission to 
carry out the study was received from all relevant authorities, namely; Higher 
Degrees Committee ethics and Medunsa Research and Ethics Committees, Dr. 
George Mukhari Academic Hospital Management and Unisa College of Agriculture 
and Environmental Sciences. Convenient sampling method was used. An overview 
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of type of data and specimens that were collected during pregnancy and at delivery 
is shown in Table 3.1. During the recruitment (prenatal visit), low vaginal and rectal 
swabs was collected by a registrar/research nurse using a cotton wool swab and 
placed in Amies transport medium (Rochelle Chemicals & Lab equipment, SA). They 
were accurately labelled and placed in a cooler box filled with ice blocks for group B 
streptococcus investigation. The specimens collected was transported from 
antenatal clinic and processed at Dr. George Mukhari Academic Hospital medical 
microbiology laboratory. At birth the infants were swabbed on the umbilicus and ear 
area for group B streptococcus cultures.  
 
Table 3.1: Types of data and specimen collection from women and babies 
                     Pregnant women         Babies  
 Recruitment                    Delivery delivery 
Questionnaire √  
GBS culture √                                          √ √ 
 
All vaginal-rectal swab specimens were cultured on a CNA agar plate and if 
negative, the swabs were inoculated into the Todd-Hewitt broth supplemented with 8 
g/ml colistin and 15g/ml gentamicin as to inhibit other normal flora (Manning et al; 
2006). The plates and tubes were incubated overnight at 37oC in the presence of 
carbon dioxide (CO2). After 24 hours of incubation, primary plates were examined for 
β-hemolytic or non-hemolytic streptococcal colonies typical of group B 
streptococcus. A single colony from each isolate was picked and sub-cultured onto 
blood agar. Plates showing no growth were further incubated for another 24 hours. 
Todd Hewitt broth was sub-cultured onto 5% sheep blood agar plates after overnight 
incubation. Two CAN agar plates were used to culture the swabs, one plate was 
divided into two to culture high vaginal and lower vaginal swabs and one plate was 
used to culture rectal swabs.  
3.5.3. GBS identification and confirmation 
Isolates were grown on a 5% sheep blood agar and identified as group B 
streptococcus by the following criteria: β-hemolysis on a 5% sheep blood agar, Gram 
staining showing gram positive cocci in pairs or short chains, negative reaction with 
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catalase reagent and Lancefield grouping with type B antisera (streptex; Biomereux 
and Remel Ltd, Europe).  
3.5.4 Catalase test 
A drop of hydrogen peroxide (H202) (30%) was placed on a clean slide, using a 
sterile inoculation loop; suspected colonies due to the presence of haemolytic activity 
were picked from the plate and be placed on a clean slide with H2O2 to determine the 
presence of Catalase enzyme in the isolate, The absence of gas bubbles indicated 
that the colony might be the GBS, since GBS is catalase positive.  
3.5.5 Gram staining 
A gram stain was done to catalase negative suspected colonies from a culture 
medium (CNA). Colonies that were Gram positive cocci were picked and subcultured 
onto 5% sheep blood agar (National Institute for Communicable Diseases (NICD)). 
After 18-24 hour incubation, colonies were picked for serological confirmation. 
3.5.6 Latex agglutination test for identification of group B streptococcus 
Seroagglutination was carried out by a slide agglutination technique using 
commercially prepared Lancefield group B Antisera. Agglutination patterns were 
linked to group B streptococcus species following manufacturer’s (Biomeurex) 
instructions. All isolates that are confirmed to be GBS were stored in microbanks 
(which it comprises of a unique cryovials System incorporating treated beads and a 
special cryopreservative solution) with different numbers and placed in a -70oC fridge 
until further analysis.  
3.5.7 Multilocus sequence typing (MLST) 
Multilocus sequence typing was performed as described by Jones et al., (2003). 
Initially DNA from each isolate was extracted with a genomic DNA isolation kit (ZR 
fungal/bacterial Zymo Research Corp, USA) following manufacturer’s instructions. 
Briefly, 100 mg (wet weight) GBS bacterial cells that have been resuspended in 200 
µl of distilled water and 750 µl lysis solutions was added to a ZR Bashing Bead lysis 
tube, and were secured in a bead beater fitted with a 2 ml tube holder assembly 
(Disruptor Genie) and were processed at a maximum speed for 5 minutes. The ZR 
Bashing Bead lysis tube were centrifuged at 10 000 Xg for a minute, then 400 µl 
supernatant were transferred to a zymo-spinTM IV spin filter in a collection tube and 
centrifuge at 7000 rpm for a minute. To the filtrate in the collection tube, 1200 µl 
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fungal/bacterial DNA Binding Buffer, 800 µl of the mixture was then transferred to a 
zymo-spin TM IIC column in a collection tube and centrifuged at 10 000 x g for a 
minute, the step was repeated.  DNA Pre-wash buffer (200 µl) was added to the 
zymo spin TM IIC column in a new collection tube and centrifuged at 10 000 x g for a 
minute, then 500 µl fungal/bacterial DNA wash buffer to the zymo spin TM IIC 
column and centrifuge at 10 000 x g for a minute. The zymo spin TM IIC column was 
transferred to a clean 1.5 ml microcentrifuge tube and 100 µl DNA elution buffer was 
then added directly to the column matrix and centrifuged at 10 000 x g for 30 
seconds to elute the DNA. The supernatant PCR template was stored at -20°C for 
the subsequence PCR amplification. 
3.5.8 Locus selection and PCR 
The following seven housekeeping genes; alcohol dehydrogenase (adhP), 
phenylalanyl tRNA synthetase (pheS), amino acid transporter (atr), glutamine 
synthetase (glnA), serine dehydratase (sdhA), glucose kinase (glcK), and 
transketolase (tkt) (Table 3.2) used for group B streptococcus characterization were 
amplified from DNA extracts by Polymerase Chain Reaction (PCR). PCR products 
were amplified with oligonucleotide primer pairs designed from the Integrated DNA 
technologies (Canada). Each 50 µl amplification reaction mixture comprised of 25 µl 
PCR master mix (Thermo scientific), 1 µl of each PCR primer (Integrated DNA 
technologies, Canada) and 5µl of group B streptococcus chromosomal DNA. The 
PCR reaction was performed in an automated thermal cycler (Applied Biosystems, 
Foster City, CA, USA). The reaction conditions were denaturation at 94°C for 1min, 
primer annealing at 55°C for 45 seconds and extension at 72°C for 1min for 30 
cycles. 
3.5.9 Detection of amplified products 
Amplified products were detected by ethidium bromide (Bio-Rad) stained agarose 
gel electrophoresis. This was done as follows: A 1.5 % gel was prepared by adding 
100ml of 0.5 X Tris-Borate-EDTA (TBE) buffer solutions to 1.5 g of agarose. The 
solution was dissolved in a microwave oven and then cooled. Five micro litre of the 
intercalating agent ethidium bromide was added to visualize amplified products when 
exposed to fluorescent light. The solution was poured into a gel tray, a comb was 
inserted and the gel left to set. Ten µl of amplified product and 5µl of loading dye 
were added into the wells of the gel. A 50 bp molecular weight marker 
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(HyperladderTM, Bioline) was used in combination with amplified product from group 
B streptococcus isolates. The gel was run at 75 V for 1hour in a 0.5 x TBE buffer 
solution. A photographic copy of the amplified products on the gel was taken with a 
Gel Doc TM EZ Imager (Bio-Rad). 
 
Extracted DNA was PCR amplified with primers listed in Table 3.2 and partial 
segments (450-500) of the PCR products were sequenced (Inqaba Biotec, Pretoria, 
South Africa). Genetic comparison of the strains was performed by constructing a 
dendrogram using CLC-bio (Inqaba Biotec, Pretoria, South Africa).  
 
Table 3.2: Oligonucleotide primers for group B streptococcus MLST (Jones et al., 
2003) 
Locus               
use 
                Name of the sequence of primer Amplicon 
size (bp) 
Forward (5’-3’)                        Reverse (5’-3’) 
adhP 
 
pheS 
 
atr 
 
glnA 
 
sdhA 
 
glcK 
 
tkt 
Amplification 
Sequencing 
Amplification 
Sequencing 
Amplification 
Sequencing 
Amplification 
Sequencing 
Amplification 
Sequencing 
Amplification 
Sequencing 
Amplification 
Sequencing 
GTTGGTCATGGTGAAGCACT 
GGTGTGTGCCATACTGATTT 
GATTAAGGAGTAGTGGCACG 
ATATCAACTCAAGAAAAGCT 
CGATTCTCTCAGCTTTGTTA 
ATGGTTGAGCCAATTATTTC 
CCGGCTACAGATGAACAATT 
AATAAAGCAATGTTTGATGG 
AGAGCAAGCTAATAGCCAAC 
AACATAGCAGAGCTCATGAT 
CTCGGAGGAACGACCATTAA 
GGTATCTTGACGCTTGAGGG 
CCAGGCTTTGATTTAGTTGA 
ACACTTCATGGTGATGGTTG 
ACTGTACCTCCAGCACGAAC 
ACAGCAGTCACAACCACTCC 
TTGAGATCGCCCATTGAAAT 
TGATGGAATTGATGGCTATG 
AAGAAATCTCTTGTGCGGAT 
CCTTGCTCAACAATAATGCC 
CTGATAATTGCCATTCCACG 
CATTGTTCCCTTCATTATC 
ATATCAGCAGCAACAAGTGC 
GGGACTTCAACTAAACCTGC 
CTTGTAACAGTATCACCGTT 
ATCGCTGCTTTAATGGCAGA 
AATAGCTTGTTGGCTTGAAA 
TGACCTAGGTCATGAGCTTT 
672 
498 
723 
501 
627 
501 
589 
498 
646 
519 
607 
459 
859 
480 
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3.5.10 Phylogenetic Analysis 
The consensus of all six isolates was drawn in CLC bio software (Inqaba Biotec, 
Pretoria, South Africa). This consensus was aligned in CLC bio software to get 
global consensus sequence.  The consensus was used to draw a UPGMA 
dendrogram and study variations in different isolates of the different serotypes of 
group B streptococcus. 
To draw a phylogenetic tree of the six isolates of group B streptococcus, only three 
genes (adhP, glnA and tkt) were used. All sequences were first aligned in the CLC 
bio software and aligned file was then subjected to UPGMA method to draw a 
phylogenetic tree. Neighbour-joining and maximum parsimony methods were used 
for the construction of phylogenetic tree. The above methods were used in 
combination with bootstrap method. 
3.5.11 Reliability, validity of the study and Statistics 
All tests were done according to standard operating procedures to ensure reliability 
and validity of the results. Data were collected and analysed using Windows Office 
Excel and SPSS software (SPSS Inc.). 
3.5.12 Ethical considerations 
The study was conducted after an approval from the Higher Degrees Committee 
ethics and Medunsa Research and Ethics Committees, Dr. George Mukhari 
Academic Hospital Management (MREC/P/02/2011: IR)  and Unisa College of 
Agriculture and Environmental Sciences (Appendix D). Pregnant Women were 
informed about the study and those who agreed to participate, signed an informed 
consent statement (see Appendix A) indicating their approval to participate. The 
information and consent statement was available in both Tswana (local) and English 
languages. The information obtained from the pregnant women was treated with 
confidentiality. All women were informed that they were free to withdraw from the 
study at any time without this having any effect on their further treatment from the 
clinic or hospital. 
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CHAPTER 4 
4. RESULTS 
4.1. Socio-demographic of the participants 
 
The socio-demographic characteristics of participating pregnant women are shown in 
Table 4.1. Four hundred and thirteen (413) pregnant women from different areas 
were recruited into the study over a period of 9 months from February 2012 to 
October 2012.  
All the pregnant women enrolled in the study were of the same racial group (blacks) 
within the age range of 18-45 years with the median age of 30 and the mean age of 
30. The pregnant women were categorised into different age groups in years as 
follows: <20, 20-24, 25-29, 30-34 35-39 and ≥40.  The majority of the participants 
were between the ages of 25-29 years (27.3%). 
 
The study participants were from different geographic areas (urban semi-urban and 
rural) surrounding Dr George Mukhari Academic Hospital. The majority of the 
participants were either single or divorced (53%), followed by married (24.3%) then 
cohabiting (22.1%) (Table 4.1). 
The participants’ educational levels were documented as follows: below matric, 
matric and tertiary level. Most had an educational level below matric (56.8%), 
followed by those who had educational level matric (29.2%) and then tertiary level 
(16.6%). Out of 413 participating pregnant women 107 were below matric, 229 were 
in matric whereas 67 were in tertiary level and there were missing data of 10 
participants. 
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Table 4.1: Socio-demographic characteristics of the pregnant women investigated 
for group B streptococcus colonization at Dr George Mukhari Hospital, Ga-Rankuwa. 
 
Socio demographic characteristics     Category                      Frequency           Percentage            
Age in years                                                             
 
 
 
 
 
 
Geographical areas                                                                       
 
 
 
Marital status        
 
 
 
Educational level                                                              
 
 
 
Employment 
 
                                                                
                       <20                                               12                                    2.98% 
                                       20-24                                           75                                   18.6% 
                                       25-29                                         110                                   27.3% 
                                       30-34                                           95                                   23.6% 
                                       35-39                                           81                                   20.1% 
                                       ≥40                                              30                                     7.4% 
  
                                      Urban                             359                                     89.1% 
                                      Semi-urban                                36                                      8.9% 
                                      Rural                                            6                                    1 .5% 
 
                                    Married                                         98                                    24.3% 
                                    Cohabiting                                   89                                     22.1% 
                                    Single/widowed/divorced            214                                      53% 
  
                                     Below matric                              229                                  56.8% 
                                     Matric                                        118                                   29.2% 
                                     Tertiary                                        67                                   16.6% 
 
                                     Unemployed                             225                                    55.8% 
                                     Employed                                 148                                    36.7% 
                     
                      
 
4.1.1 Overall colonization 
Pregnant women were classified as being group B streptococcus colonized, if the 
bacterium was isolated from the vagina, the rectum or both and confirmed by antigen 
detection. The participants were regarded as non-colonised if there was no group B 
streptococcus isolated from all the sites mentioned above. Group B streptococcus 
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colonization was detected in 128/413 (30.9%) of pregnant women with gestational 
age from 4-37 weeks.  
4.1.2 Comparison between media used to culture 
The importance of selective enrichment broth and selective plating is shown in Table 
4.2 below, the comparison between the selective direct plate (CNA agar plate) and 
selective broth enrichment (Todd-Hewitt) was performed on 413 samples of which 
128 of the samples tested positive.  Seventy (54.7%) of Group B streptococcus 
positive samples were recovered from using Todd-Hewitt broth, whereas 45.3% 
were recovered from CNA agar plate. From  58 colonised pregnant women, 12 had 
strains cultured only from vaginal swabs, while 22 had strains isolated only from the 
rectal swabs and another 24 had strains isolated simultaneously from both the 
vaginal and rectal swabs when cultured on a CNA agar plate.  
Table 4.2: Comparison between Todd-Hewitt broth and CNA media  
 
GBS colonised 
pregnant women 
 
   Type of medium  
 
   Site of recovery from CNA media 
 
 
 
 128 
 
CNA 
 
Todd-
Hewitt 
broth 
 
    RS LVS HVS All sites 
(RS,LVS,H
VS) 
 
    58 
 
      70 
 
    22 
 
(37.9.2%) 
 
 
    9 
 
(15.5%) 
 
 
   3 
 
(5.2%) 
 
 
   24 
 
(41.4%) 
 
 
 
4.1.3 Variables associated/not-associated with GBS colonization 
The age range (18-45) distribution of the group B streptococcus colonised pregnant 
women were compared. Among the group B streptococcus colonised pregnant 
women, group B streptococcus colonization rate was higher in the 25-29 age group 
and the colonization rate was lower in <20 age group (Figure 4.1). 
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Figure 4.1: Distribution of 128 group B streptococcus isolated among different age 
interval of the study participants. 
 
4.2 Adverse pregnancy outcomes 
Adverse pregnancy outcomes were categorised into miscarriages, HIV positive and 
still birth while pregnant women who were currently colonised with group B 
streptococcus and had miscarriages previously were 32/85  and those who had 
stillbirth were 12/23 (Table 4.3). 
 
 
 
 
 
 
 
<20 
1% 
20-24 
22% 
25-29 
31% 
30-34 
19% 
35-39 
19% 
≥40 
8% 
Age distribution 
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Table 4.3: Variables associated with group B Streptococcus colonization in pregnant 
women, George Mukhari academic hospital; Ga-Rankuwa. 
                                          
                             N (number)          %GBS  colonization                                                                           
HIV status 
Positive                              52                      40                             
Negative                             72                     56       
Parity  
0                                         38                      37                            
1-2                                      68                      30                            
≥3                                       19                      28                            
 
Still birth 
0                                         113                        33                             
1-2                                       12                         55                              
≥3                                          0                          0                              
Total GBS colonisation       12                52 
 
Miscarriage 
0                                          93                          29                             
1-2                                       29                          37                             
≥3                                          3                          43                             
Total GBS colonisation        32                      38 
 
 
4.1.4 Neonates born to colonised pregnant women 
Out of 128 colonised pregnant women, only 39 of their newborn babies were 
involved in the study. This was because most pregnant women gave birth without 
giving notice to the registry or a nurse involved in the study for the swabs to be 
taken.  The neonates were supposed to be classified as being colonized if group B 
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streptococcus was isolated from any of the two specimens (ear or cord). However, 
there were no positive results obtained. 
4.3. Multilocus sequence typing 
 
4.3.1. PCR and Sequencing 
Due to time and resource limitations, a representative proportion of each capsular 
type was randomly selected for further analysis using multilocus sequence typing. In 
this study, a total of seven group B streptococcus isolates were used, each 
representing serotype group (Ia, Ib, II, III, IV, and V) recovered at Dr George Mukhari 
Academic hospital. Genomic DNA was extracted from seven isolates and seven 
housekeeping gene fragments were amplified (PCR), were negative control was 
used to ensure that there was no contamination and sequenced using the 
corresponding primers that are listed in Table 3.2 (in a previous chapter).  
To check if the PCR had worked and that there was no contamination in the negative 
controls, the samples were run on an agarose gel to separate DNA molecules 
according to their size and ensure purity.  Most of the genes could be amplified 
successfully except the following gene and samples; glcK 113, adhP 1 and 113, glnA 
4 and 113, sdhA 6, pheS 6, and atr 1 and 2. Clear specific bands of expected sizes 
were observed and it was easy to differentiate these from non- specific bands 
(Appendix C). Table 4.5 gives the summary of agarose gel electrophoresis 
(Appendix C) results from PCR products amplified with corresponding 
oligonucleotide primers of seven housekeeping genes. The negative sign (-) shows 
that there was no band observed when visualizing amplified products exposed to 
fluorescent light, whereas positive (+) sign shows that the band was available, which 
proves that the PCR has worked.  
 
 
 
 
35 
 
Table 4.4: Summary of agarose gel electrophoresis (Appendix C) results from PCR 
products amplified with corresponding oligonucleotide primers. 
 
Isolates 
 ID                    adhP           pheS            atr              glnA                sdhA            glcK                tkt            
 
1 - +      -                +         +           +              + 
2                        + +      -                 +          +           +              + 
4  + +     +                  -          +           +              + 
6  + -      +                 +             -           +              + 
12  + +      +                  +             +           +              + 
65  + +      +                  +             +           +              + 
113  - +      +                   -              +            -              + 
Isolate 1 represent GBS serotype III, isolate 2 GBS IV, isolate 4 GBS serotype III, isolate 6 
represent GBS serotype Ia, isolate 12 represent GBS V, isolate 65 represent GBS Ib and isolate 
113 represent serotype II.  
ID=Identity, adhP= alcohol dehydrogenase, pheS = phenylalanyl tRNA synthetase, atr =amino 
acid transporter, glnA= glutamine synthetase, sdhA = serine dehydratase, glcK = glucose 
kinase, and tkt = transketolase, (-) = negative, (+) = positive. 
 
To proceed with the sequencing, PCR products undergone quality control test, 
where they were purified to remove all the primers, nucleotides, enzymes, salts and 
other impurities from the DNA samples that might interfere with the sequencing 
process.  In this study, 49 samples (which comprises of seven isolates and seven 
genes from each isolates) undergone quality control test, where only 10 samples out 
of 49 samples failed the quality control test, therefore only 39 samples were 
sequenced. The following samples; atr 12, sdhA 113 and pheS 4 were unable to be 
edited because they contained mixed templates that was confirmed by a second 
sequencing reaction and therefore, they were not used for analysis.  
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4.4. Consensus Sequences of the housekeeping genes 
For the seven isolates of the group B streptococcus, the sequences obtained at each 
of the seven loci were compared with each other. Figure 4.2 shows the alignment of 
the consensus sequence based on three genes (adhP, glnA and tkt) sequenced 
successfully for the six isolates of the group B streptococcus, the global consensus 
sequence is shown at the base and identical bases are marked with dots. Conserved 
residues are shown with their corresponding symbols. The alignment of all the 
consensus sequences helped to study the highly conserved residues in the isolates 
of group B streptococcus. Figure 4.3 shows the UPGMA dendrogram (CLC bio 
software); that represent the relatedness of group B streptococcus isolates. A default 
value of 1000 was used in bootstrap analysis and the values are present at each 
branch. The different sample numbers at the ends of the branches are external 
nodes. The lengths of the branches between the nodes illustrate the differences in 
nucleotide sequences between the isolates. Thus, the tree illustrates phylogenetic 
relationships between the sequence types. The relationships are presented as a 
rooted tree with branch lengths being proportional to the estimated genetic distance 
between the strains of group B streptococcus. The scale bars represent the number 
of nucleotide differences. Since not all the genes were covered for all the samples; 
the dendrogram was constructed using the most complete set of genes of the 
following isolates; 1, 6, 65, 2, 4 and 12, except for 113 isolate.  The allelic profiles for 
the isolates were not recorded.  
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Figure 4.2: Multiple sequence alignment of consensus sequences of the isolate one 
to six (1, 6, 65, 2, 4 and 12) of the group B streptococcus. A reduced form alignment 
showing only the differences for the data set was used in the UPGMA tree. 
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Figure 4.3: Phylogenetic tree of group B streptococcus consensus alignment tree 
isolates sequences constructed using CLC Bio. The dendrogram was a consensus 
of 1000 bootstrap trees generated with the neighbour-joining algorithm with the use 
of sequence data for three genes (adhP, glnA and tkt). 
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CHAPTER 5 
5. DISCUSSION 
5.1. Epidemiology of group B streptococcus 
This was a descriptive, prospective study with a population of 413 pregnant women 
seeking antenatal care at Dr George Mukhari Academic Hospital. However, selection 
bias might have occurred. Some women attending antenatal care may not have 
been recruited into the study due to lack of staff and time at the study sites. 
However, these pregnant women were likely not to differ from the study participants. 
The numbers of pregnant women not recruited due to this reason, as well as the 
number of women who declined recruitment to the study were not recorded. Data on 
participants’ socio-demographic were not available for ten (2.4%) of the pregnant 
women originally recruited to the study. Group B streptococcus culture was 
performed on every specimen. The missing data during this part of the study are 
therefore, unlikely to represent a bias with respect to group B streptococcus status. 
5.1.1. Colonization rate 
The key findings of the study were that, the estimated maternal colonization rate of 
group B streptococcus colonisation was 30.9%. The finding of this study is high 
when compared to colonization rate from some other African countries like 
Mozambique which reported colonization rate of 1.8% (De Steenwinkel et al., 2008). 
The difference in colonization rate reported from Mozambique and the present study 
may be due to source of blood used for culture for isolation of group B streptococcus 
and geographic difference can also contribute to the difference. However, higher 
rates have been reported from two previous studies (35% and 54%) in Europe 
(Bergh et al., 2004; Bergseng et al., 2008) and the other study (47%) from Zimbabwe 
(Mavenyengwa et al., 2009). The reasons for this significant colonization rate in this 
study were unclear, though; the contributory factors might include the specimen 
collection and culture medium used. The use of selective enrichment broth is 
recommended to maximise the isolation of group B streptococcus and to avoid the 
overgrowth of the other microorganism, because vaginal and in particular rectal flora 
contains numerous microorganisms (Ferrieri et al., 1977). The cohort’s gestation age 
in this study was from 4-40 weeks which differs with what Bergeron et al., (2000) 
used in their study, where they cultured specimens at 35-37 weeks gestation. 
45 
 
When direct agar plating was used instead of selective enrichment broth, as many as 
50% of woman who are group B streptococcus carriers have false-negative culture 
results (Laboratory practices for prenatal Group B streptococcal screening and 
reporting, 1999). The isolation rate of group B streptococcus strains was improved 
by selective enrichment broth (Todd-Hewitt broth) in this study, where the swabs that 
showed no colonization when cultured on a CNA agar plate, tested positive when 
inoculated in a Todd-Hewitt broth. These false-negative culture results were proved 
by Ferrieri et al., (1977) and Kubota (2002) who did not use selective culture medium 
and only found the prevalence rates of 5.6% and 11.4%, whereas with studies that 
used selective medium, reported rates of 19.8% and 18.6% (Madzivhandila et al., 
2011;Valkenburg-van den Berg, et al., 2006). 
 In some scientific reports, the different positive culture rates in the variety of culture 
media was shown, and in the different areas of specimen collection (Yang et al., 
2012), the rectal swabs exclusion to detect group B streptococcus colonization may 
compromise the sensitivity in group B streptococcus colonization detection (Stoll and 
Schuchat., 1998). Transmission rates range from 29% to 85% in most studies, low 
rates as 12% have been reported from countries where low colonization  rates has 
been found irrespective of the adequate microbiological methods used (Edwards and 
Baker.,2000; McKenna and Iams., 1998). The culture methods used in this study 
was an internationally renowned method using lower vaginal and rectal swabs 
cultured both in enrichment broth and on a solid agar plate media.  
In various studies there are no significant differences in colonization rates noted on 
the basis of age or parity, but increasing age and parity (Anthony et al., 1978; Yow et 
al., 1980) have also sometimes been associated with lower rates of carriage. 
However, Regan et al (1991) described group B streptococcus carriage as being 
more common among older women and women of lower parity. In this study, no 
association between colonization and age or parity was found.  This correspond to 
study done by Valkenburg-van den Berg, et al., (2006), where they found no 
association between colonization, parity and age. 
5.1.2. Group B streptococcus and Ethnic groups 
Characteristics of the population studied can also explain differences in group B 
streptococcus colonization rates. The group B streptococcus colonization rate 
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among black pregnant women both in United States and South Africa has been 
shown to be higher (Dzowela et al., 2005). Comparison between different ethnic 
groups was limited in this study, since all pregnant women enrolled were of the same 
ethnic group.  
5.1.3. Risk factors for GBS colonization 
There are many predisposing factors which have previously been reported to be 
associated with an increased risk of group B streptococcus colonization and as a 
result the neonate has an increased risk of group B streptococcus infection. The 
factors that were investigated in this study include reproductive history and illness, 
delivery methods and HIV status. The study aimed at correlating the pregnant 
women’s current group B streptococcus status with their past pregnancy history, 
because group B streptococcus was previously reported as being associated with 
pre-term delivery, miscarriages, still birth and parity. 
Although the importance of infection as a cause of preterm delivery is gaining 
recognition, little is known about the role of group B streptococcus infection in 
miscarriages. McDonald et al., (2000) stated that group B streptococcus was a key 
pathogen in unsuspected intrauterine infections underlying spontaneous 
midgestation abortions. The study of Daugaard (1988) demonstrated an association 
between the occurrence of group B streptococci in the urine and cervix and late 
spontaneous abortions, but El Kersh et al. (2002) found no correlation with a history 
of repeated spontaneous miscarriages. There was no relation between pregnant 
women who had a history of miscarriages, stillbirth and group B streptococcus 
carriage, though there was a report, of Group B streptococcus colonised pregnant 
woman originally from Zimbabwe who was reported to give birth to a macerated 
baby (foetus), and due to the condition, swabs were not taken for analysis, so there 
is no prove of group B streptococcus being the cause of the maceration. There was 
another report of group B streptococcus pregnant woman who was admitted in a 
hospital because she experienced no foetus movement for a period of a week, and 
she was found to have uterine foetus death. Due to the situation, no swabs were 
taken, there’s no prove of group B streptococcus being the cause of the foetus 
death.  
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The majority of group B streptococcus colonised pregnant women were unable to 
report back when they come back to give birth, this resulted in having a smaller 
cohort of the neonates than it was expected. Only 39 (30.5%) neonates from 128 
colonized pregnant women participated in the study; represented the whole 
population of the neonates. It was documented that, most neonates were born by 
caesarean and this limited the comparison between colonized neonates born by 
caesarean and those born by normal birth. 
5.2. Multilocus sequence typing (MLST) 
Typing of bacterial strains and isolates remains an important aspect in epidemiology 
and microbiological research. The process of MLST analysis is very specific and 
therefore it is unlikely that strains have the same sequence type due to chance alone 
(Jones et al., 2003). The samples analyzed in this study were limited in number due 
to time and resource limitations but a representative of each capsular types (which 
was done in the other part of the study) was randomly selected for further analysis 
using multilocus sequence typing to provide a snapshot of a larger cohort and 
information about the strains of group B streptococcus circulating in the population of 
interest at Dr. George Mukhari Academic hospital. Some of the amplification 
products (samples) were not edited because they contained mixed templates. No 
analysis on the sample was done. Thus, only samples with no mixed templates were 
edited and used for analysis.  
 
The group B streptococcus polysaccharide capsule is determined by genes in the 
capsular polysaccharide locus, which encodes enzymes for polysaccharides 
synthesis (Cieslewicz et al., 2005 and Yim et al., 1997). No isolate of serotype VI, VII 
and VIII was found among the strains isolated from Dr George Mukhari Academic 
Hospital but only Ia-V. Isolates representing Ia, Ib, II, III, IV and V was used for 
MLST to represent the population.  The most common strain was serotype III, which 
is the reason why two strains, representing III, were used for multilocus sequence 
typing (MLST) analysis.  
Multiple alignment construction corresponds to developing a hypothesis of how a 
number of sequences have evolved through the processes of character substitution, 
insertion and deletion. The input to multiple alignment algorithms is a number of 
homologous sequences; that is sequences that share a common ancestor and most 
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often also share molecular function. The generated alignment in figure 4.2 where 
each row corresponds to an input sequence and each column corresponds to a 
position in the alignment. An individual column in the table represents residues that 
have all diverged from a common ancestral residue. Gaps in the table (represented 
by a '-') represent positions where residues have been inserted or deleted and thus 
do not have ancestral counterparts in all sequences.  
The allelic profile, characteristics such as G+C (guanine+cytosine) content and  the 
proportions of nucleotide alterations that led to a change in the amino acid sequence 
(non-synonymous substitution, dN) and the proportions of nucleotide alterations that 
did not lead to a change in the amino acid sequence (synonymous substitution, dS) 
ratio were not analysed or calculated because of the smaller sample size used in this 
study as it is compared with the study done by Jones et al., (2003) where they used 
MLST to characterize a collection of 152 of globally and ecologically diverse human 
strains of group B streptococcus that included representatives of capsular types Ia, 
Ib, II, III, V, VI and VIII. The combination of their alleles of their results at the house 
keeping loci provided an allelic profile or sequence type for each isolate. Similar 
results might have been obtained if the same sample size was used. By saying that, 
the MLST method was unsuccessful in this study. With the phylogenetic analysis, the 
UPGMA tree based on differences in consensus of the isolates showed that all group 
B streptococcus isolates are clustered and descend from a single node. 
5.3. Limitations  
There was a high number of absenteeism of colonised pregnant women to give birth, 
which resulted in a smaller cohort of the neonates to the study. Most neonates who 
were involved in the study were born by caesarean section. Larger cohorts would 
have enabled the comparison between neonates born from colonised pregnant 
women by caesarean and normal vaginal birth. While this research serves as a good 
pilot study for further MLST analysis, major limitations exist. The most crucial of 
these limitations of the study was the small sample size, especially with MLST 
analysis. For characterization of GBS isolates a representative selection of seven of 
128 GBS Isolates in total were chosen. The isolates were randomly chosen, but 
were selected to represent all serotypes isolated. There was a low quality of PCR 
products and therefore low quality sequencing results, only a small percentage of the 
original cultured data was available for MLST analysis. The resources that were 
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supposed to be used to achieve objectives were quite limited. This ultimately posed 
a major problem for achieving the set objectives. 
5.4. Conclusions 
The population used for this study was unique due to the age, socioeconomic 
background, and ethnic group in the patients visiting the study clinic at Dr George 
Mukhari academic hospital. This study revealed that pregnant women of all ages are 
at risk of group B streptococcus, and screening process must be implemented and 
every pregnant woman must be screened for group B streptococcus. A number of 
studies have documented that the accuracy of prenatal screening cultures in 
identifying intrapartum colonization status can be enhanced by careful attention to 
the timing of cultures, the anatomic sites swabbed and the laboratory procedures 
used for culture and detection of the organisms (Schrag et al, 2002). This study has 
provided the valuable knowledge regarding group B streptococcus colonisation at Dr 
George Mukhari Academic Hospital. This had also provided a foundation for further 
studies on group B streptococcus prevalence in pregnant women and their babies. 
The results confirmed that the combination of Todd-Hewitt broth and CNA agar plate 
is a time saving and sensitive method. A larger sample size would have enabled 
trends in data to be shown with more statistical power and certainty. Only three loci 
for six samples were successfully sequenced out of seven housekeeping genes. 
5.5. Recommendations 
 
1. More research studies need to be done in diverse and rural communities in 
South Africa to determine group B streptococcus prevalence. 
2. Future studies should also investigate the persistence of group B 
streptococcus 
3. The molecular studies on group B streptococcus using MLST and other 
advanced and sensitive techniques should be carried out.  
 
 
 
 
50 
 
8. REFERENCES 
 
Adler, A., Block, C., Engelstein, D., Hochner-Celnikcier, D., Drai-Hassid, R., Moses, 
A.E. 2008.  Culture-based methods for detection and identification of Streptococcus 
agalactiae in pregnant women—what are we missing? Eur J Clin Microbiol Infect Dis; 
27:241–243. 
Anthony, B.F., Okada, D.M. and Hobel, C.J. 1978. Epidemiology of the group B 
streptococcus: longitudinal observations during pregnancy. J Infect Dis; 137(5): 524-
530. 
Baker C.J. 1990. Antibiotic therapy in neonates whose mothers have received 
intrapartum group B streptococcal chemoprophylaxis. Pediatr Infect Dis J, 9:149–150 
Baker, C. 2000. Group B streptococcal infections in streptococcal infections, D. 
Stevens and Kaplan, E. (eds).N Y oxf univ Pr, 222-237. 
Baker, C.J., Kasper, D.L., Tager, I.B., Pareeks, A., Alpert, S. McCormack, W.M. and 
Goroff, D. 1977. Quantitative determination of antibody to capsular polysaccharide in 
infection with type III strains of group B streptococcus. J. clin invest. 59; 810-818. 
Basham, L. E., Pavliak, V., Li, X., Hawwari, A., Kotloff, K.L., Eldelman, R. and 
Fatton, A. 1996. A simple, quantitative, reproducible avidin-biotin ELISA for the 
evaluation of group B Streptococcus type-specific antibodies in humans. Vac.14, 
439-445. 
Batalis, N.I., Caplan, M.J. and Schandl, C.A. 2007. Acute deaths in nonpregnant 
adults due to invasive streptococcal infections. Am J Forensics Med pathol. 28(1):63-
8  
Beal, S. and Dancer, S. 2006. Antenatal prevention of neonatal group B 
streptococcal infection. Gynaecological and perinatal practice. 6: 218-225. 
Beitune, P.I., Duarte, G. and Maffei, L.M.C. 2005. Colonization by streptococcus 
agalactiae during pregnancy: maternal and perinatal prognosis. Brazilian J infect Dis. 
9: 413-8670. 
51 
 
Berg, S., Kasvis, S., Trollfors, B., Pilichowska-Paszkiet, J., Flattom, A., Tessin, I. and 
Lagergard T. 1998. Antibodies to group B streptococci in neonates and infant. Infect 
Dis.157: 221-224. 
Bergh, K., A. Stoelhaug, K. Loeseth, and L. Bevanger. 2004. Detection of group B 
streptococci (GBS) in vaginal swabs using real-time PCR with TaqMan probe 
hybridization. Indian J Med Res 119 Suppl: 221-223. 
Bergseng, H., L. Bevanger, M. Rygg, and K. Bergh. 2007. Real-time PCR targeting 
the sip gene for detection of group B Streptococcus colonization in pregnant women 
at delivery. J Med Microbiol. 56:223-228. 
Berkley, J.A, Lowe, B.S., Mwangi, I., Williams, T., Bauni, E., Mwarumba, S., et al. 
2005. Bacteremia among children admitted to a rural hospital in Kenya. N Engl J. 
Med. 352:39–47. 
 
Bhushan, R., Anthony, B.F. and Frasch, C.E. 1998. Estimation of group B 
streptococcus type III polysaccharide specific antibody concentrations in human sera 
is antigen dependent. Infect and Immun.66:5848-5853. 
Blumberg, H. M., Stephens, D. S., Modansky, M. Erwin, M., Elliot, J. Facklam, R. R., 
Schuchat, A., Baughman, W. and M. M. Farley. 1996. Invasive group B streptococcal 
disease: the emergence of serotype V. J. Infect. Dis. 173:365-373. 
 
Bomela, H.N., Ballot, D.E. and Cooper, P.A. 2001. Is Prophylaxis of early-onset 
group B Streptococcus diseases appropriate for South Africa.  South African Med 
J.91: 858-860. 
 
Bou, G., Figueira, M., Canel, D., Cartelle, M., Eiros, J.M. and Villanueva, R. 2005 
Evaluation of group B streptococcus differential agar for detection and isolation of 
Streptococcus agalactiae. Clin Microbiol Infect. 11:676–678. 
 
Boyer, K. M., Gadzala, C. A., Kelly, P. D., Burd, L. I. and Gotoff, S. P. (1983). 
Selective intrapartum chemoprophylaxis of neonatal group B streptococcal early-
onset disease. II. Predictive value of prenatal cultures. J. Infect Dis. 148: 802–809. 
 
52 
 
Boyer KM and Gotoff SP. 1986. Prevention of early-onset neonatal group B 
Streptococcal disease with selective intrapartum chemoprophylaxis. N Engl JMed 
314:1665-669. 
Brimil, N., Barthell, E., Heindrichs, U., Kuhn, M., Lutticken, R. and Spellerberg, B. 
(2006).Epidemiology of Streptococcus agalactiae colonization in Germany. 
International J. Med Microbiol. 296: 39–44. 
Burnham, C.D. and Tyrrell, G.J. 2003. Virulence factors of group B streptococci. 
Review Med Microbiol. 14:109-118. 
 
Busetti M., D’Agaro P. and Campello C.2007. Group B Streptococcus prevalence in 
pregnant women from North-Eastern Italy: advantages of a screening strategy based 
on direct plating plus broth enrichment. J. of Clin Path. 60:1140- 1143. 
 
Centers for Disease Control and Prevention. 2002. Prevention of Perinatal Group B 
Streptococcal Disease. MMWR Morbidity Mortality Weekly Rep 51:1-24.  
 
Cieslewicz, M.J., Chaffin, D., Glusman, G., Kasper, D., Madan, A., Rodrigues, S., 
Fahey, J., Wessel, M.R., Rubens, C.E. 2005.Structural and genetic diversity of group 
B Streptococcus capsular polysaccharides. Infect. Immun. 73:3096-3103. 
Chan, C.E.Z., Chan, A.H.Y., Hanson, B.J. and Ooi, E.E. 2009.The use of antibodies 
in the treatment of infectious diseases. Singapore Med J.50 (7):663-673. 
Cooper, J.E. and Feil, E.S. 2004. Multilocus sequence typing –what is resolved? 
Trends in microbiology. 12(8) 371-377. 
Cutland, C.L., Madhi, S.A., Zell, E.R., Kuwanda L. and Laque M. 2009. 
Chlorhexidine maternal-vaginal and neonate body wipes in sepsis and vertical 
transmission of pathogenic bacteria in South Africa: a randomised controlled trial. 
Lancet.6736: 1–8. 
 
53 
 
Daugaard, H.O, Thomsen, A.C, Henriques, U. and Ostergaard, A. 1988.Group B 
streptococci in the lower urogenital tract and late abortions. Am J Obstet Gynecol. 
158 (1):28-31. 
 
Davies, H.D., Adair, C., McGeer, A., Ma, D., Robertson, S., Mucenski, M., Kawalsky, 
L., Yrell, G. and Baker C.J. 2001. Antibodies to capsular polysaccharide of group B 
streptococcus in pregnant Canadian women: Relationship to colonization status and 
infection in the neonate. J. infect Dis.184: 285-291. 
De Steenwinkel, D.O., Tak, H.U., Muller, A.E., Nouwen, J.L., Oostvogel, P.M. and 
Mocumbi, S.M. 2008. Low carriage rate of group B Streptococcus in pregnant 
women in Maputo, Mozambique. Trop Med Int health. 13:427- 429. 
 
Delannoy, C.M.J., Crumlish, M., Fontaine, M.C., Pollock, J., Foster, G., Dagleish, M., 
Turnbull, J.F. and Zadoks, R.N. 2013. Human streptococcus agalactiae strains in 
aquatic mammals and fish. BMC Microbiology. 13:41. 
 
Doran, K.S., Nizet, V. 2004. Molecular pathogenesis of neonatal Group B 
streptococcal infection: no longer in its infancy. Mol Microbiol. 54: 23–31. 
Dawodu, A.H., Damole, I.O. and Onile, B.A. 1983. Epidemiology of group B 
streptococcal carriage among pregnant women and their neonates: an African 
experience. Trop Geographic Med. 35:145–50. 
 
Dzowela, T.K. and  Igbigbi, A. 2005. Prevalence of GBS colonization in antenatal 
women at Queen Elizabeth Central Hospital, Blantyre. Malawi Med J.17(3) 97-99. 
Edmond, K.M, Kortsalioudaki, C., Scott, S., Schrag, S.J., Zaidi, A.K.M., Cousens, S 
and Heath, P.T. 2012. Group B streptococcal disease in infants aged younger than 3 
months: systematic review and meta-analysis. Lancet. 379:574-556 
Edwards, M.S. and Baker, C.J. 2001. Group B streptococcal infections. In: 
Remington JS, Klein JO, eds. Infectious diseases of the fetus and newborn infant. 
Philadelphia: W. B. Saunders. 5:1091–156. 
 
54 
 
Edwards, M.S, Rench, M.A, Palazzi, D.L. and Baker, C.J. 2005.Group B 
streptococcal colonization and serotype-specific immunity in healthy elderly persons. 
Clin infect Dis. 40: 352-357. 
El-Kersh, T., Al-Nuaim, L., Kharfy, T., Al-Shammary, F., Al-Saleh, S. and Al-Zamel, 
F. 2002. Detection of Genital Colonization of Group B Streptococci during Late 
Pregnancy. Saudi Med. J. 23(1): 447-452.  
 
Elliott, J. A., Farmer, K. D. and Facklam. R. R. 1998. Sudden increase in isolation of 
group B streptococci, serotype V, is not due to emergence of a new pulsed-field gel 
electrophoresis type. J. Clin Microbiol. 36:2115-2116. 
 
English, M., Ngama, M., Musumba, C., Wamola, B., Bwika, J., Mohammed S, et al. 
2003. Causes and outcome of young infant admissions to a Kenyan district hospital. 
Arch Dis Child. 88:438–443. 
 
Facklam.,R.R., Padula., J.F., Wortham., E.C., Cooksey.R.C. and Rountree., H.A. 
1979. Presumptive identification of Group A,B and D streptococci on agar plate 
media. Clinical microbiology. 9(6): 665-672. 
Farley, M.M. 2001. Group B streptococcal disease in non-pregnant adults. J. clin 
infec. 3: 556-561. 
Faro, J.P., Bishop, K., Riddle, G., Ramirez, M.M, Katz, A.R., Turrentine, M.A. and 
Faro, S. 2013. Accuracy of an accelerated, culture based assay for detection of 
group B streptococcus. Inf disease in obstetrics and gynecology. Hindawi publishing 
corporation. 1-4. 
Feil, E.J., Li, B.C. and Aanensen DM. 2004. eBURST: inferring patterns of 
evolutionary descent among clusters of related bacterial genotypes from multilocus 
sequence typing data. J. Bact. 186(5):1518-1530. 
 
Ferrieri, P., Cleary, P.P and Seeds, A.E. 1977. Epidemiology of group B 
streptococcal carriage in pregnant women and newborn infants. J. Med Microbiol. 
10: 103-114. 
 
55 
 
Forbes, B.A., Sahn, D.F and Weissfield, D.F. 2007. Diagnostic microbiology. Andrew 
Atlen, 2nd edition. Pg 37. 
Fry RM. Fatal infections by haemolytic streptococcus group B. 1938. Lancet. 1:199- 
201. 
Gonza´lez-Outeirin˜o, J., Kadirvelraj, R. and Woods, R.J. 2004. Structural elucidation 
of type III group B Streptococcus capsular polysaccharide using molecular dynamics 
simulations: the role of sialic acid. Carbohydrate Research.340: 1007-1018. 
Gottof, S.P., Odell, C., Papierniak, C.K., Klegerman., M.E. and Boyer, K.M. 1986. 
Human IgG antibody to group B streptococcus type III: Comparison of protective 
levels in a murine model with levels in infected human neonates. J Infect Dis. 153(3): 
511–519.  
 
Grimwood, K., Stone, P.R., Gosling, I.A., et al. 2002. Late antenatal carriage of 
group B Streptococcus by New Zealand women. Aust N Z J Obstet Gynecol.; 
42(2):182–6.  
 
Guttormsen, H.K., Baker, C.J., Nahm, M.H., Paoletti, L.C., Zughaier, S.M., Edwards, 
M.S. and Kasper, D.L. 2002. Type III group B streptococcal polysaccharide induces 
antibodies that cross-react with streptococcus pneunoniae type 14. Infect and 
Immunity. 70: 1724-1738. 
 
 
Harrison, L.H., Elliott, J.A., Dwyer, D.M., Libonati, J.P., Ferrieri, P., Billmann, L., and 
Schuchat, A. 1998. Serotype distribution of invasive group B streptococcal isolates in 
Maryland: implications for vaccine formulation. Maryland Emerging Infections 
Program. J. Infect Dis.177; 998-1002. 
Hemming, V. G., R. T., Hall, P. G., Rhodes, A. O. Shigeoka, and Hill. H. R. 1976. 
Assessment of group B streptococcal opsonins in human and rabbit serum by 
neutrophil chemiluminescence. J. Clin. Invest. 58:1379-1387. 
 
Hickman, M.E., Rench, M.A., Ferrieri, P., and Baker, C.J. 1999. Changing 
epidemiology of group B streptococcal colonization. Paediatrics.104: 203-209. 
56 
 
Hillier, S.L., Baker, C.J., Ferrieri, P. and Krohn MA. 2001. Could a vaccine against 
group B streptococcus protect against vaginal colonization. Program and abstracts of 
the 2nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San 
Diego). Washington, DC: American Society for Microbiology: 239. 
 
Javanmanesh, F. and Eshraghi, N. 2013. Prevalence of positive recto-vaginal culture 
for group B streptococcus in pregnant women at 35-37 weeks of gestation. Medical 
Journal of Islamic republic of Iran; 27(1):7-11. 
Jolley, K.A., Feil, E.J., Chan, M.S. and Maiden, M.C.J. 2001. Sequence type analysis 
and recombinational tests (START). Bioinformatics 17:1230–1231. 
 
Jones, N., Bohnsack J.F., Takahashi, S., Oliver, K.A., Man-Suen C., Kunst, F., 
Glaser, P., Rusniok, C., Crook, D.W. M. Rosalind., M. Harding R.M., Bisharat, N. and 
Spratt, B.G. 2003. Multilocus Sequence Typing System for Group B Streptococcus. 
J. clin Microbiol. 41(6): 2530-2536. 
 
Johri, A.K., Paoletti, L.C., Glaser, P., Due, M., Sharma, P.K., Grandi, G., Rappuoli, 
R. 2006. Group B Streptococcus: global incidence and vaccine development. Nat. 
Rev. Microbiol. 4: 932-942. 
 
Kubota T. 1998. Relationship between maternal group B streptococcal colonization 
and pregnancy outcome. Obstet Gynecol. 92(6):926–30. 
 
Kumar S, Tamura K, Nei M. MEGA3: (2004) Integrated software for Molecular 
Evolutionary Genetics Analysis and sequence alignment. Brief Bioinform. 5(2):150-
63. 
Lachenauer, C. S., Baker, C. J., Baron, M. J., Kasper, D. L., Gravekamp, C. and 
Madoff, L. C. 2002. Quantitative determination of immunoglobulin G specific for 
group B streptococcal beta C protein in human maternal serum. J Infect Dis. 185: 
368–374. 
Lachenauer, C.S., Kasper, D.L., Shimanda, J., Ichiman, Y., Ohtsuka, M., Kaku, M., 
Paoletti, L.C., Ferrieri, P. and Madoff, L.C. 1999. Serotypes VI and VIII predominate 
57 
 
among Group B streptococci Isolated from pregnant Japanese Women. J. infect 
Dis.179:1030-1033.  
Lancefield, R.C. 1934. A Serological Differentiation of Specific Types of Bovine 
Hemolytic Streptococci (Group B). J Exp Med. 59: 441–458. 
 
Lancefield, R.C., McCarty M. and Everly, W.N. 1975. Multiple mouse– protective 
antibodies directed against group B streptococci. Special reference to antibodies 
effective against protein antigens. J. Exp Med.142: 165-179. 
Law, MR., Palomaki, G., Alfirewic, Z., Gilbert, R., Heath, P., McCartney, C., Reid, T 
and Shrag, S. 2005. The prevention of neonatal group streptococcal disease: a 
report by a working group of medical screening society. Med screen. 12: 60-68. 
Larsson, C., Lindroth, M., Nordin, P., Stalhammar-Carlemlm, M., Lindahl, G. and 
Krantz, I. 2006. Association between low concentrations of antibodies to protein α 
and Rib and invasive neonatal group B Streptococcal infection. Neonatal ED.91: 
403-408. 
Laving, A.M., Musoke, R.N., Wasunna, A.O.  and Revathi, G. 2003. Neonatal 
bacterial meningitis at the newborn unit of Kenyatta National Hospital. East Africa 
Medical Journal: 80:456–62. 
 
Lessa, A.L.S, Krebs, V.L.J, Brasil, T.B, Pontes, G.N., Carneiro—Sampaio, M and 
Palmeira, P. 2011. Preterm and term neonates transplacentally acquire IgG 
antibodies specific to LPS from Klebsiella pneumoniae, Escherichia coli and 
Pseudomonas aeruginosa. Fed of Euro Microbiol. 62: 236-243. 
Lin, F.Y., Philips, J.B. 3rd, Azimi, P.H., et al. 2001. Level of maternal antibody 
required to protect neonates against early-onset disease caused by type 1a group B 
streptococcus: a multicenter, seroepidemiology study. J Infect. 184:1022–8. 
 
Madhi, S. A., Radebe, K., Crewe-Brown, H., Frasch, C. E., Arakere, G., 
Mokhachane, M. and Kimura, A. 2003. High burden of invasive Streptococcus 
agalactiae disease in South African infants. Ann Trop Paediatric. 23: 15–23. 
 
58 
 
Madzivhandila M., Adrian P.V., Cutland C.L., Kuwanda L., Schrag S.J. Madhi S.A. 
2011.Serotype distribution and invasive potential of GBS isolates causing diseases 
in infants and colonizing maternal-newborn dyads. PLoS One: 6(3):17861. 
Maiden, M.C. 2006. Multilocus sequence typing of bacteria. Annual review of 
microbiol. 60: 561-588. 
Maiden, M.C., Bygraves, J.A, Feil E., et al. 1998.  Multilocus sequence typing: a 
portable approach to the identification of clones within populations of pathogenic 
microorganisms. Proc Natl Acad Sci U S A. 95(6):3140-5. 
 
Manning, S.D., Wood, S., Kasha, K., Martin, D., Rioux, S., Brodeur, B. and Davies, 
H.D. (2006).Naturally occurring antibodies for the group B streptococcal surface 
immunogenic protein (Sip) in pregnant women and newborn babies. Vaccine. 24: 
6905-6912. 
Mason, P.R., Katzenstein, D.A., Chimbira, T. and Turick, M. 1989. The puerperal 
sepsis study group: Microbial flora of lower genital tract of women in labour Harare 
Maternity Hospital. Central African J. medicine. 35(3):337-344. 
Matlova, J., Strakova, L., Urbanskova, P., Sak, P., Sever, T. 2004. Vaginal and rectal 
carriage of streptococcus agalactiae in the Czech Republic: incidence, serotypes 
distribution and susceptibility to antibiotics. Indian J. Med Research 
119(supplements): 84-87.  
Mavenyengwa, R.T., Masunga, P., Meque, E., Kudinha, T., Moyo, S. R, Bevanger, 
L., Bergh, K., Nziramasanga P, and Mapako T. 2006. Streptococcus agalactiae 
(group B Streptococcus (GBS) colonization and persistence, in pregnancy; a 
comparison of two diverse communities (rural and urban). Cent Afr J Med. 52:38-43. 
 
Mavenyengwa, R.T., Maeland J.A. and Moyo, S.R. 2008. Distinctive features of 
surface-anchored proteins of Streptococcus agalactiae strains from Zimbabwe 
revealed by PCR and dot blotting. Clin Vaccine Immunol. 15: 1420-1424. 
Mavenyengwa, R.T, Maeland, J.A. and Moyo, S.R. 2009. A putative novel surface-
exposed Streptococcus agalactiae protein frequently expressed by the group B 
Streptococcus from Zimbabwe. Clin Vaccine Immunol. 16:1302-1308. 
59 
 
Mazade, M .A. and Edwards, M .S. 2001. Impairment of Type III Group B 
Streptococcus-Stimulated Superoxide Production and Opsonophagocytosis by 
Neutrophils in Diabetes1.Molecular genetics and metabolism. 73: 259-267. 
McDonald HM, Chambers HM. Intrauterine infection and spontaneous midgestation 
abortion: is the spectrum of microorganisms similar to that in preterm labor? Infect 
Dis Obstet Gynecol. 8(6): 220-227 
McKenna D.S. and Iams J.D. 1998. Group B Streptococcal infections. Seminars in 
perinatology. 22: 267-276. 
Maiden, M. C., Bygraves, J. A., Feil, E. et al. 1998. Multilocus sequence typing: a 
portable approach to the identification of clones within populations of pathogenic 
microorganisms. Proc Natl Acad Sci USA. 95: 3140–3145. 
 
Michon, F., Brisson, J.R., Dell, A., Kasper, D.L. and Jennings, H.J. 1988 
Multiantennary group specific polysaccharide of group B Streptococcus. 
Biochemistry. 27: 5341–5351. 
 
Michon, F., Katzenellenbogen, E., Kasper, D.L. and Jennings, H.J. 1987. Structure 
of the complex group-specific polysaccharide of group B Streptococcus. 
Biochemistry 26: 476–486. 
 
Mims, C., Dockrel. H.M., Goering, R.V., Roit, I., Wakelin, D. and Zuckerman, M. 
2004. Medical microbiology.  St Lous Sudney Toronto. pg. 318. 
Manning, S.D., Betsy, F., Carl, L., Patricia, T., Carol, J. and Mark, D. 2003. 
Correlates of Antibiotic-Resistant Group B Streptococcus Isolated From Pregnant 
Women. Am J Obstet and Gynecol 101:74 –79. 
 
Milledge J., Calis, J.C., Graham S.M., et al. 2005. Aetiology of neonatal sepsis in 
Blantyre, Malawi: 1996-2001. Ann Trop Paediatrics. 25:101-110. 
 
Moyo SR, Mudzori J, Tswana SA, and Maeland JA: Prevalence. 2000. capsular type 
distribution, anthropometric and obstetric factors of group B Streptococcus 
60 
 
(Streptococcus agalactiae) colonization in pregnancy. Cent Afr J Med. 46(5):115-
120. 
Moyo, S.R., Maeland, J.A. and Mudzori, J. 2001. Antibodies against streptococcus 
agalactiae protein cα and R4 in sera from pregnant women from Norway and 
Zimbabwe. Clin and diag laboratory Immunol. 8: 1110-1114. 
Moyo SR, Maeland JA, and Bergh K. 2002. Typing of human isolates of 
Streptococcus agalactiae (group B streptococcus, GBS) strains from Zimbabwe. J 
Med Microbiol. 51(7):595-600. 
 
Murray, P.R., Rosenthal, K.S., Kobayash, G.S. and Pfaller, M.A. 2002. Medical 
Microbiology. Library of Congress cotaging in publication data, 4th edition. Pg. 106-
107. 
Nathoo, K.J., Mason, P.R. and Chimbira, T.H. 1990. Neonatal septicaemia in Harare 
Hospital: aetiology and risk factors. The Puerperal Sepsis Study Group. Central Afri 
J. Med. 36:150–6. 
 
Palmeira, P., Quinello, C., Silveira-Lessa., A.C., Zago, C.A. and Carneiro-Sampio, 
M. 2011. IgG placental transfer in healthy and pathological pregnancies. Clin and 
develop Immunol. The review article. 
Paoletti, L.C. and Johnson, K.D. 1995. Purification of preparative quantities of group 
B streptococcus type III oligosaccharides. J. chromatography. 705: 363-364. 
Phares, C.R., Lynfield, R., Farley, M.M., Mohle-Boetani, J., Harrison, L.H., Petit, S., 
Craig, A.S., Schaffner, W., Zansky, S.M., Gershman, K., Stefonek, K.R., Albanese, 
B.A., Zell, E.R., Schuchat, A. and Schrag, S.J. 2008. Epidemiology of invasive group 
B streptococcal disease in the United States, 1999-2005. JAMA. 299:2056-65. 
 
Polin, R.A., Douglas, S.D., Kasper, D.L. and Baker, C.J. 1982. Enzyme-Linked 
immunosorbent Assay for measurement of antibody to type III group B streptococci. 
Journal of clinical microbiology.15: 991-993.  
 
61 
 
Pulver, L.S., Hopfenbeck, M.M., Young, P.C., Stoddard, G.J., Korgenski K., Daly, J. 
and Byington, C.L. 2009. Continued early onset group B Streptococcal infections in 
the era of intrapartum prophylaxis. J.  Perinatal. 29:20-25. 
 
Radtke, A. 2012. Molecular Methods for Typing of Streptococcus agalactiae with 
Special Emphasis on the development and Validation of a multi -Locus Variable 
Number of Tandem Repeats Assay (MLVA). Thesis, 28. 
 
Regan, J.A., Klebanoff, M.A. and Nugent, R.P. 1991. The epidemiology of group B 
streptococcal colonization in pregnancy. Vaginal Infections and Prematurity Study 
Group. Obstet Gynae. 77:604–10. 
Robbins, J.B., Schneerson, R., Vann, W.F., Bryla, D.A. and Fattom A. 1995. 
Prevention of systemic infections caused by group B streptococcus and 
Staphylococcus aureus by multivalent polysaccharide–protein conjugate vaccines. 
Annm N Y Acad Sci. 754:68–82. 
 
Saleem, S., Rouse, D.J., McClure, E.M., Zaidi, T., Reza, Y., Yahya, I. A., Memon, N. 
H., Khan, G., Memon, N.H., Soomro, N., Pasha, O., Wright, L. L., Moore, J. and 
Goldenberg R. L. 2010. Chlorhexidine vaginal and infant wipes to reduce perinatal 
mortality and morbidity: a randomized controlled trial. Obstet and Gynae. 115 
(6):1225-32. 
 
Schrag, S., Gorwitz, R., Fultz-Butts, K. and Schuchat, A. 2002. Prevention of 
perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR 
Recommend Rep. 51: 1–22. 
 
Schrag, S.J., Zywicki, S., Farley, M.M., Reingold, A.L., Harrison, L.H., Lefkowitz, 
L.B., Hadler, J.L. 2000. Group B streptococcal disease in the era of intrapartum 
antibiotic prophylaxis.  J.  Med: 432: 15-20. 
Schwartz, J., Robison-Dunn, B., Makin, J., Bobby, L. and Boynton, J. 2012. 
Evaluation of the BD MAX GBS assay to detect streptococcus group B in Lim broth-
enriched anterpartum vaginal-rectal specimens. Diagn Microbiol and infect Dis. 73: 
97-98  
62 
 
Sharmila, V., Joseph, N.M, Arun, B.T., Chaturvedula, L. and Sistla S. 2011 Genital 
tract group B streptococcal colonization in pregnant women: a South Indian 
perspective. J Infect Dev Ctries. 5(8): 592-5. 
 
Shen, X., Lagergard, T., Yang, Y., Linndblad, M., Fredriksson, M and Holmgren, J. 
(2001). Preparation and preclinical evaluation of experimental group B streptococcus 
type III polysaccharide–cholera toxin B subunit conjugate vaccine for intranasal 
immunization. Vaccine. 19: 850-861. 
Shet, A. and Ferrieri, P. 2004. Neonatal & maternal group B Streptococcal infections: 
A comprehensive review. Indian J Med Res 120:141-150. 
 
Slotved, H., Kong, F., Lambertsen, S.S. and Gilbert, G.L. 2007. Serotype IX, a 
Proposed New Streptococcus agalactiae Serotype. J. of Microbiol. 45(9): 2929-2936 
Sorensen, U.B.S., Poulsen, K., Ghezzo, C., Margarit, I. and Kilian, M. 2010. 
Emergence and Global Dissemination of Host-Specific Streptococcus agalactiae 
Clones. MBio. 1(3):e00178-10. 
 
Stapleton, R.D., Kahn, J.M., Evans, L.E., Critchlow, C.W. and Gardella, C.M. 2005. 
Risk factors for group B streptococcal genitourinary tract colonization in pregnant 
women. Obstet Gynecol.106: 1246–1252. 
 
Stoll, B.J. and Schuchat, A. 1998. Maternal carriage of group B streptococci in 
developing countries. Paedia infect Dis J. 17: 499—503. 
Suara, R.O., Adegbola, R.A., Mulholland, E.K., Greenwood, B.M. and Baker, C.J. 
(1998) Seroprevalance of antibodies to group B streptococcal polysaccharides in 
Gambian mothers and their newborns. J. of national med ass. 90: 109-114. 
Takahashi, S., Aoyagi, Y., Adderson, E.E., Okuwaki, Y. and Bohnsack, J.F. 1999. 
Capsular sialic acid limits C5a production on type III group B streptococci. Infect and 
immunity. 67: 1866-1870. 
63 
 
Tien, N., Ho, C., Lin, H., Shih, M., Ho, M., Lin, H., Lin, H., Chang, C. and Lu, J.  
2011. Multilocus sequence typing of invasive group B Streptococcus in central area 
of Taiwan. J. of microbiol, immuno and infect. 44: 430-434. 
 
Trikha, M, Yan, L. and Nakada, M.T. 2002. Monoclonal antibodies and therapeutics 
–oncology current opinion in Biotechnology. 13: 609-614. 
Tsui HY, Ip M, Ng P, Sahota DS, Leung T and Lau T. 2009. Change in prevalence of 
group B Streptococcus maternal colonization in Hong Kong. Hong Kong Medic 
J.15:C1-66. 
 
Valkenburg-van den Berg A., Sprij, A., Oostvogel, P., Mutsaers J., Renes W., 
Rosendaal F. and Dorr P. 2006. Prevalence of colonization with group B streptococci 
in pregnant women of a multi-ethic population in Netherlands. Gynaecology 
Reproduction Biology.  Euro J. of Obstetric. 124: 178-183. 
 
Verani, J.R., Mcgee, L. and Schrag, S.J. 2010. Prevention of Perinatal Group B 
Streptococcal Disease Revised Guidelines from Centres for Disease Control and 
Prevention. MMWR. 59(10): 1-32.   
 
Wilson, K. and walker, J. 2005. Principles and techniques of biochemistry and 
molecular biology, 6th edition Cambridge university, Inc. Hong Kong .pp 574 -5790. 
Wastfelt, M., Stalhammar-Carlemalm, M. and Delisse, A.M. 1996. Identification of a 
family of streptococcal surface proteins with extremely repetitive structure. J of Biol 
Chem: 271(31):18892-7. 
 
Yang, M.-J., Sun, P.L., Wen, K.-C., Chao, K.-C., Chang, W.-H., Chen, C.Y. and 
Wang, P.-H. 2012. Prevalence of maternal group B streptococcus colonization and 
vertical transmission in low-risk women in a single institute. J. of the Chinese med 
ass. 75: 25-28. 
 
Yeung, S. and Davie, E.G. 2005. Infection in the fetus and neonate, foetal infection 
medicine. 33-34. 
64 
 
Yim, H. H., Nittayarin, A. and Rubens, C. E. Analysis of the capsule synthesis locus, 
a virulence factor in group B streptococci. 1997. Adv. Exp Med Biol: 418:995e7. 
 
Yow, M.D, Leeds, L.J, Thompson, P.K, Mason, E.O., Clark, D.J. and Beachler, C.W. 
1980. The natural history of group B streptococcal colonization in the pregnant 
woman and her offspring. I. Colonization studies. J. Obstetric Gynae. 137(1):34–38. 
 
Zaleznik, D.F., Rench, M.A., Hillier, S., Krohn, M.A., Platt, R. and Lee ML. 2000. 
Invasive disease due to group B Streptococcus in pregnant women and neonates 
from diverse population groups. Clin Infect Dis. 30:276-81. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
65 
 
APPENDIX A 
Consent Form 
 
This is a Research Project of University of South Africa in collaboration with 
the University of Limpopo Medunsa campus and the Polytechnic of Namibia.  
 
Title of research project: Epidemiology and multilocus sequence typing of group B 
streptococcus colonising pregnant women and their neonates at Dr George Mukhari 
Hospital, Pretoria. 
Participant (mother)‘s informed consent 
You (mother) and your newborn baby are being invited to take part in a research 
study that investigate group B streptococcus. Group B streptococcus is a bacterium 
that is found naturally in birth canal and digestive system in pregnant women and it 
can cause infection such as in blood (septicaemia), lungs (pneumonia) and can 
damage brain linings (meningitis), body surface (sepsis). Group B streptococcus can 
lead to miscarriage, stillborn, or even death after being born.  
Procedures 
You (mother) will be asked to provide a sample of blood (5 ml) and vaginal-rectal 
swab specimens. The results of the study of your samples will be used for research 
purposes only and will remain confidential.  
Privacy: 
Your research record is confidential. Your identity and all personal and confidential 
information about you will not be divulged to any participating scientist. A coded 
number will be given to the specimen, and used by the investigators for reference 
only. Participating scientists will not have access to your identity. 
 
Risks and benefits: 
The risks associated with this study are slight discomfort when blood sample is 
collected. It is important to know you will not benefit from the study, as this is not a 
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treatment study.  We cannot and do not guarantee or promise that you will receive 
any benefits from this study and you will not get paid to participate in this study.   
 
Time involvement: 
Your participation will take approximately 10 minutes  
 
If I sign, can I withdraw from the research later? 
If you decide to participate, you are free to withdraw from participating in this study at 
any time.  After any revocation, your study data will no longer be used.  
 
B. I hereby consent voluntarily to participate in the above mentioned study: 
 
I (Mother ‘s name) ……………………………………hereby voluntarily  consent and  
allow me and my newborn baby………………………………………….to take part in 
the above mentioned project. 
 
I declare that: 
• I have read or had read to me this information and consent form and I 
understand what is required of me. 
• I have had a chance to ask question and all my questions were adequately 
answered. 
• I understand that taking part in this study is voluntary and we have not been 
pressurized to take part. 
• I may choose to leave the study at any time and will not penalized or prejudice 
in anyway. 
• My decision whether or not to participate in this study will not affect my 
medical care. 
• My privacy will be maintained in all published and written data resulting from 
the study.   
 
Signed at……………………………………..on……………………………2012 
                        (Place)                                          (Date) 
 
Signature …………………………          signature of the witness………………………. 
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Declaration by a Senior Researcher 
 
I ( Name)……………………………………………..declare that: 
• I have  explained the information in this document to the participant of this 
study  
• I have encouraged her to ask questions and take time to answer them.  
• I have endeavored to make her understand all aspects of the research. 
 
Signed at……………………………………………..on…………………………2012 
(Place)                                                  (Date) 
 
…………………………………….                        ………………………………… 
Signature of the Senior Researcher                                   
 
Signature of the witness.......................................... Date....................... 
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APPENDIX B 
 
GBS STUDY QUESTIONNAIRE  
 
 
PART I 
 
Patient Name:                            _____________________               
 
 
Date Recruited                          |__|____|____|__|__|__| 
                                                     (DD/   MM/     YY) 
 
Study Number    |__|__|__|__| 
 
Hospital/Clinic Number           |__|__|__|__|__|__|__| 
 
Home Address                          ________________________ 
                                                  ________________________ 
                                                  ________________________ 
Contact Tel No                         ________________________ 
 
Date of birth                             |__|____|____|__|__|__| 
                                                    (DD/   MM/     YY) 
 
 
Age (years)                               |__|__|__| 
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Socio-economic characteristics 
 
 
                                          Married/ Single/ Divorced/ Widowed/Cohabiting 
Marital status                           |__||__||__||__||__| 
 
 
                                                 1. Below Matric 2. Matric   3. Tertiary level    
Level of Education Reached              |__|                 |__|            |__|  
 
                                                Yes No 
Employed                                |__||__| 
 
 
Salary per month (Rand)        |__|__|__|__|__|__| 
 
 
 
  Managerial                   Semi-Skilled   skilled     Unskilled 
Occupation                             |__|                 ||__|         |__| 
                                               Yes No 
Husband/Partner employed   |__||__| 
 
 
                                                                  1. Below Matric   2.Matric 3. Tertiary level    
Husband/Partner Level of Education Reached |__|                   |__|             |__| 
 
Husband/Partner Salary per month (Rand)                         |__|__|__|__|__| 
 
                                        Own   Rent    Lodge Under guardianship of relative 
Accommodation               |__|      |__|       |__|                          |__| 
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Dwelling most during the year     Urban    Rural   Semi-urban 
                                                          |__|     |__|         |__| 
 
Obstetric History 
                                                                   Yes        No 
Antibiotic treatment in the last 14 days       |__|          |__| 
 
Parity                                           |__|__| 
 
No. of previous miscarriages       |__|__| 
 
No. of previous stillbirths            |__|__| 
 
No. of previous normal  
Vaginal deliveries                         |__|__| 
 
Present pregnancy 
 
Last menstrual period (LMP)       |__|____|____|__|__|__| 
                                                     (DD/   MM/    YY) 
 
                                           Sure          Unsure      Unknown 
Date                                      |__|            |__|              |__| 
 
                                          Booked   Unbooked 
Booking status                       |__|         |__| 
 
Expected date of delivery |__|____|____|__|__|__| 
                                                     (DD/   MM/    YY 
History of Flu-like illness               Yes        No  
in early pregnancy                            |__||__| 
If yes, for how long (in weeks) |__|__| 
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                                                      Yes  No 
Trauma in pregnancy                      |__||__| 
 
Specify                                       (If yes) _______________________ 
                                                   _____________________________ 
                                                   _____________________________ 
 
Any vaginal discharge requiring  
                                                                        Yes      No 
Treatment during current pregnancy                |__|     |__| 
 
Height (cm)                                                  |__|__|__| 
 
Weight (Kg) at first ANC visit                     |__|__|__| 
 
Subsequent Weight                                                 |__|__|__|     Date……….. 
 
Mid-arm circumference (cm)                       |__|__|__| 
 
Blood group                                                  _________________________ 
 
                                                                    Yes    No 
VDRL test                                                  |__||__| 
 
                                                                    Yes     No 
TPHA test                                                    |__||__| 
 
HIV status                                                 Pos       Neg     If Pos: CD count …………
           |__ |       |__| 
On HAART                                                PMTCT              None. 
|__|                                |__|                          |__|  
  
Comorbid illness: ……………………… 
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APPENDIX C 
 
     NC       MW      1          2          4        6            12      65       113 
 
Fig C1: Genomic DNA from group B streptococcus strains (different serotypes; Ia, Ib, 
II, III, IV and V) subjected to PCR with oligonucleotide primer pairs of glcK (glucose 
kinase). Showing the 607bp PCR product (lanes 1-7). Lane MW, molecular weight 
marker (50bp ladder). 
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     MW     1        2          4         6         12      65       113     Neg Control 
 
Fig C2: Genomic DNA from group B streptococcus strains (different serotypes; Ia, Ib, 
II, III, IV and V) subjected to PCR with oligonucleotide primer pairs of glnA 
(glutamine synthetase). Showing the 589bp PCR product (lanes 1-7). Lane MW, 
molecular weight marker (50bp ladder). 
 
 MW        1           2         4         6          12        65     113       Neg Control          
 
Fig C3: Genomic DNA from group B streptococcus strains (different serotypes; Ia, Ib, 
II, III, IV and V) subjected to PCR with oligonucleotide primer pairs of adhP (alcohol 
dehydrogenase). Showing the 672bp PCR product (lanes 1-7). Lane MW, molecular 
weight marker (50bp ladder). 
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       MW     1        2      4      6          12      65     113      Neg Control 
 
Fig C4: Genomic DNA from group B streptococcus strains (different serotypes; Ia, Ib, 
II, III, IV and V) subjected to PCR with oligonucleotide primer pairs of sdhA (serine 
dehydratase). Showing the 646bp PCR product (lanes 1-7). Lane MW, molecular 
weight marker (50bp ladder). 
 
 
         MW      1      2        4        6        12      65       113    Neg control 
 
Fig C5: Genomic DNA from group B streptococcus strains (different serotypes; Ia, Ib, 
II, III, IV and V) subjected to PCR with oligonucleotide primer pairs of atr (amino acid 
75 
 
transporter). Showing the 627bp PCR product (lanes 1-7). Lane MW, molecular 
weight marker (50bp ladder). 
             MW   1         2       4         6        12     65      113    Neg Control 
 
Fig C6: Genomic DNA from group B streptococcus strains (different serotypes; Ia, Ib, 
II, III, IV and V) subjected to PCR with oligonucleotide primer pairs of tkt 
(transketolase). Showing the 859bp PCR product (lanes 1-7). Lane MW, molecular 
weight marker (50bp ladder). 
    MW   1         2         4        6       12        65     113   Neg control 
 
Fig C7: Genomic DNA from group B streptococcus strains (different serotypes; Ia, Ib, 
II, III, IV and V) subjected to PCR with oligonucleotide primer pairs of pheS 
(phenylalanyl tRNA synthetase). Showing the 723bp PCR product (lanes 1-7). Lane 
MW, molecular weight marker (50bp ladder). 
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